君实生物
TopAlliance

2025

Environmental, Social and Governance (ESG) Report


Shanghai Junshi Biosciences Co., Ltd.



Stock code: 688180.SH; 1877.HK

CONTENTS

About This Report 01
Board Statement 02
Junshi Biosciences at a Glance 03
Honors and Awards 04
Key Performance 75
Index 80
Reader Feedback Form 86



Enhancing ESG Governance and Advancing Sustainable Development

ESG Management Structure 07
Stakeholder Engagement 09
Materiality Assessment 10



Strengthening Governance Foundations and Upholding Compliance

Corporate Governance 12
Investor Relations 15
Compliant Operation 17
Business Ethics 19




Focusing on Patient Needs to Unleash Innovative Momentum

Product Quality and Service 22
Data Security and Customer Privacy 27
Supply Chain Management 29
Innovation-driven Development 33
Intellectual Property Protection 42



Fulfilling Environmental Responsibilities to Protect Our Green Home

Environmental Compliance Management 45
Resource and Energy Utilization 47
Pollutant and Waste Management 51
Addressing Climate Change 55
Circular Economy 58



Safeguarding Life and Health and Undertaking Social Responsibility

Employee Rights 60
Talent Development 63
Occupational Health 67
Social Welfare and Inclusive Medical Care 71
Industry Empowerment 73

About This Report

Introduction

This is the Environmental, Social, and Governance (ESG) Report publicly released by Shanghai Junshi Biosciences Co., Ltd. to comprehensively and authentically present its management practices and achievements in the environmental, social, and governance domains during its operations to shareholders, employees, regulatory bodies, customers, partners, the public, and other stakeholders.

Reporting Scope

This report covers Shanghai Junshi Biosciences Co., Ltd. and its subsidiaries. It is published annually, covering the period from January 1, 2025, to December 31, 2025, with certain content or data extending to prior years or forward-looking to subsequent years.

Appellation Description

In this report, "Junshi Biosciences", "the Company", and "we" all refer to Shanghai Junshi Biosciences Co., Ltd.

Data Sources

All data used in this report are sourced from the Company and its officially issued documents and reports. Financial data in this report are denominated in Renminbi (RMB), unless otherwise specifically noted.

Preparation Basis

This report has been prepared in accordance with Appendix C2 "Environmental, Social and Governance Reporting Guide" of the *Main Board Listing Rules* of the Stock Exchange of Hong Kong Limited, *Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 14 – Sustainability Report (Trial Implementation)*, the Global Reporting Initiative Sustainability Reporting Standards (GRI Standards), and the United Nations' 17 Sustainable Development Goals (SDGs).

Reporting principles

- Materiality: Through ongoing dialogue with stakeholders and in light of the Company's industry characteristics and operational context, a materiality assessment was conducted to identify and prioritize issues most significant to both the Company and its stakeholders. These issues form the core focus of disclosures in this report.
- Quantification: Explanations are provided regarding the definitions and fluctuations of selected indicators to help stakeholders clearly and accurately understand the Company's key performance.
- Consistency: Data are reported using consistent methodologies aligned with the reporting period and the boundaries of consolidated financial statements; any changes in scope or methodology are clearly disclosed to ensure comparability.
- Balance: This report strives to present the Company's ESG information in a complete, objective, and balanced manner.

Access to this Report

You may download the electronic version of this report from the official websites of the Shanghai Stock Exchange (www.sse.com.cn), the Stock Exchange of Hong Kong Limited (www.hkex.com.hk), and Shanghai Junshi Biosciences Co., Ltd. (www.junshipharma.com) to access additional corporate social responsibility information.

Board Statement

Dear shareholders, partners, and friends from all sectors of society:

As the highest decision-making and supervisory body for environmental, social, and governance (ESG) affairs at Shanghai Junshi Biosciences Co., Ltd., the Board of Directors has consistently integrated sustainability deeply into the core of the Company's strategy and business operations. We firmly believe that adhering to compliance baselines, focusing on innovative value, and fulfilling social responsibilities are fundamental to achieving long-term, resilient growth and represent the essential commitment of a pharmaceutical company to meet societal expectations and safeguard life and health.

The Board of Directors continues to strengthen the ESG governance framework, supervising the management in refining a system characterized by "strategic leadership, structural assurance, and full employee engagement". We have fully incorporated key ESG issues into the Company's overall risk management and decision-making processes. Based on our business characteristics and stakeholder concerns, we have systematically assessed and identified core ESG topics, including corporate governance, compliant operations, innovation-driven growth, product quality, environmental management, employee rights, and accessible healthcare. This ensures that our resources are precisely allocated to critical needs, fostering deep synergy between ESG and our core business.

In governance and compliance, in 2025 the Board of Directors oversaw the optimization of the Company's governance structure. In accordance with laws, regulations, and regulatory documents, the Board of Supervisors was abolished, and its statutory functions under the *Company Law of the People's Republic of China* were assumed by the Audit Committee of the Board of Directors. Concurrently, core governance documents, including the *Articles of Association*, were revised, and the operational mechanisms of the five specialized Board committees were enhanced to ensure scientifically sound and transparent decision-making. The Company upholds the core values of "Quality First, Truth-seeking, Integrity and Compliance, Pursuit of Excellence" and has upgraded its "end-to-end, all-scenario, and all-employee" compliance governance system. By leveraging AI to enhance compliance management and delivering over 60 compliance training sessions—achieving full employee coverage—the Company recorded zero incidents of commercial bribery, unfair competition, or other violations throughout the year, thereby reinforcing the foundation of compliant operations.

In innovation and value creation, the Board of Directors fully supports the Company's patient-centric R&D strategy and the development of an integrated global R&D system. In 2025, the Company's core product toripalimab received approval for two additional indications, bringing the total number of approved indications to twelve—all of which have been included in the National Reimbursement Drug List. Multiple pipeline products have entered Phase III clinical trials or marketing application stage. During the reporting period, the Company accelerated clinical development of several globally competitive innovative therapeutics, including the PD-1/VEGF bispecific antibody (JS207), EGFR/HER3 ADC (JS212), PD-1/IL-2 fusion protein (JS213), marking the beginning of its global clinical exploration. Over 135 research findings were presented at international academic conferences, and more than 200 research papers were published in leading international journals, underscoring the global competitiveness of China's innovative medicines.

In terms of environment and sustainable operations, the Board of Directors supervises the Company's adherence to the resource utilization policy of "resource conservation, pollution control, compliance with laws, continuous improvement, and green development". We have promoted ISO 14001 environmental management system certification across all our manufacturing sites. The Company has implemented energy-saving and consumption-reduction projects, such as photovoltaic power generation and steam condensate reuse, to optimize the efficiency of energy and water resource utilization. We strictly control the emissions of waste gas, wastewater, and waste materials, achieving a 100% compliance rate for the disposal of hazardous waste. Through technological innovation and process optimization, we continue to enhance our environmental performance.

In social responsibility and stakeholder engagement, the Company places high priority on employee rights and development and is committed to building an inclusive talent empowerment system. Throughout the year, it delivered over 300 training sessions, with an average of over 100 training hours per employee. Compensation incentives and career development pathways have been enhanced to protect employees' legitimate rights and interests. Meanwhile, the Company actively fulfills its social responsibilities by engaging in public welfare initiatives, including primary healthcare support, pro bono medical consultations, and health education programs, promoting equitable access to healthcare and demonstrating its commitment as a responsible corporate citizen.

The Board of Directors affirms that the Company will steadfastly uphold its philosophy of openness, collaboration, and shared success; maintain strict compliance, deepen innovation-driven development, and fulfill its social responsibilities. It will continuously enhance ESG management and performance to create long-term value for shareholders, employees, patients, partners, and society at large, contribute to the high-quality and sustainable development of the industry, and steadily advance toward its vision of becoming an innovative pharmaceutical company rooted in China with a global footprint.

Shanghai Junshi Biosciences Co., Ltd.
Board of Directors
March 2026

Junshi Biosciences at a Glance

Established in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company committed to the discovery, development, and commercialization of innovative therapies. The Company was listed on the Main Board of the Stock Exchange of Hong Kong Limited in December 2018 and on the STAR Market of the Shanghai Stock Exchange in July 2020. With exceptional capabilities in drug discovery, cutting-edge biotechnology research, and large-scale manufacturing, Junshi Biosciences has built a robust portfolio of products with significant market potential and a well-structured pipeline. The self-development and external cooperation of the Company on a global scale is realized based on its early research in the R&D centers in the United States, Suzhou and Shanghai, while the commercialization process of the Company is optimized by its production bases in Wujiang, Suzhou and Lingang, Shanghai. The Company has all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain, aiming to become an innovative pharmaceutical company based in China and with a global reach.

Vision

To become an innovative pharmaceutical company in China for global, and to benefit human health

Mission

To provide patients with world-class, trustworthy, and innovative drugs

Core Values

Quality First

Truth-seeking


Integrity and Compliance

Pursuit of Excellence



Honors and Awards

January 2025



2024 JRJ "Golden Intelligence Award" for Excellence in the Pharmaceutical and Biotechnology Industry

JRJ

January 2025



Outstanding Employer 2025

51job

April 2025



2024 Outstanding Contribution Award of Pudong New Area

The People's Government of Pudong New Area, Shanghai

May 2025



2025 Top 100 Listed Healthcare Companies by Innovation Capability

VCBeat, VBEF

May 2025



2024 China Innovative Drug Value Ranking – Top 20 Biopharmaceutical Companies; 2024 China Innovative Drug Value Ranking – Top 50 Comprehensive Companies

Yaozh.com, PharmChina

June 2025



2025 China Top 20 Pharmaceutical Companies by Comprehensive R&D Strength; 2025 China Top 20 Biopharmaceutical Companies by R&D Strength

Yaozh.com, 2025 Parenteral Drug Industry Congress & Top 100 Chinese Pharmaceutical Companies List Release

July 2025



Best Process Compliance Award

National Drug Clinical Trial Institution, Peking University Cancer Hospital Yunnan


July 2025



Case of Internationalization of Local Innovation

Nomination Committee for Sustainable Innovation Cases in Healthcare (initiated by China Business Network, HealthInsight, and the Medical Service Committee of the Shanghai Service Federation)

August 2025



2025 Top 101 Innovative Pharmaceutical Companies in China

The 7th CMC-CHINA Expo, 2025 Top 101 Chinese Pharmaceutical Enterprises, and Top 10 Core Industry Chain Rankings

September 2025



2025 Hardcore Technology R&D Endeavor Award

China Business Journal

September 2025



Industry-Leading Innovative Drug "Toripalimab"; Industry-Leading Biotech Company

Pharmcube, China's Decade of Glory for Innovative Drugs List

November 2025



2025 Golden Bull Award for Growth Value

China Securities Journal

November 2025



2025 Leading Enterprise in the Globalization of China's Innovative Drugs

Stellar Biotech, iiMedia Research

November 2025



Top 50 Enterprises by Growth Rate in the Pharmaceutical Industry (2024–2025); Top 50 Enterprises by Independent Innovation in the Pharmaceutical Industry (2024–2025)

All-China Federation of Industry & Commerce Medical & Pharmaceutical Industry Chamber

November 2025



2025 Top 100 Chinese Innovative Pharmaceutical Companies

Healthcare Executive

November 2025



2025 Model Unit for Science Popularization Benefiting the Public

China Anti-Cancer Association

December 2025



Most Valuable Pharmaceutical Company

ZhiTong Financial, 10th ZhiTong Financial Listed Company Awards

December 2025



First Prize of Huaxia Medical Science and Technology Award – Science and Technology Award for "Establishment and Application of New Technologies, New Schemes and New Strategies for Stratified Comprehensive Treatment of Recurrent Nasopharyngeal Carcinoma"

China International Exchange and Promotive Association for Medical and Healthcare

January 2026



Top 50 in R&D Intensity; Top 100 Shanghai Hardcore Technology Enterprises 2025

Shanghai Industrial Technology Innovation Promotion Association, 2025 Top 100 Hardcore Technology Enterprises in Shanghai

01

Enhancing ESG Governance and Advancing Sustainable Development

Junshi Biosciences regards ESG governance as the core enabler of its sustainable development and has established a management system characterized by "strategic leadership, structural assurance, and full employee engagement". By clarifying the board's strategic responsibilities, establishing dedicated working groups, and implementing regular communication and review mechanisms, the Company deeply embeds ESG principles across its entire business value chain, systematically manages various risks, and precisely addresses stakeholder expectations—advancing coordinated development between the Company, society, and the environment through standardized governance.



17 PARTNERSHIPS FOR THE GOALS

ESG Management Structure

The Company places great emphasis on fulfilling its corporate social responsibility (hereinafter referred to as the "CSR") and is committed to co-creating sustainable value with stakeholders across environmental, social, and economic dimensions. In formulating its strategic plans, the Company fully integrates its CSR strategy, pays close attention to environmental, social, and governance (ESG)-related risks during internal and external risk assessments, and develops corresponding mitigation strategies. Furthermore, the Company actively cultivates CSR awareness among all employees, promotes organization-wide participation, and effectively embeds CSR into daily business operations.

The Company's Board of Directors participates in environmental, social, and governance matters, assumes strategic responsibility, and oversees implementation. The Company has established an ESG working group comprised of the Board Secretary and key personnels from Securities Department, Production Management Center, Quality Management Center, and other relevant departments, to be responsible for ESG-related matters. Other functional departments collaborate with the working group to implement practical activities on corporate social responsibility topics, ensuring that CSR principles and practices are embedded throughout the entire operational lifecycle.

Decision-making level	Board of Directors	Participates in environmental, social, and governance matters, assumes strategic responsibility, and oversees implementation
Management level	Environmental, social, and governance working group	Responsible for the specific implementation of environmental, social, and governance initiatives
Execution level	Other functional departments	Collaborates with the working group to carry out practical activities on corporate social responsibility topics, ensuring that CSR principles and practices are embedded throughout the entire operational lifecycle

The Company regularly publishes ESG reports and holds discussions centered on ESG goals set by the board. A routine review mechanism is in place to periodically receive updates on ESG progress. By integrating internal evaluations with external expert input, the Company comprehensively assesses goal attainment to ensure deep alignment with business development and adherence to the principles of measurability and achievability.



Strategy and practice

The Company deeply embeds ESG principles across the entire "R&D–production–commercialization" value chain, serving as a strategic compass for enterprise development. We recognize that sustainable development is a long-term mission—one that underpins the continuity of innovation, defines the ethical foundation of our operations, and ultimately determines whether we earn the enduring trust of all stakeholders.



The Company regards environmental protection as a cornerstone of sustainable development. Adhering to the resource use policy of "resource conservation, pollution control, compliance with laws, continuous improvement, and green development", the Company has established and implemented a scientific and effective environmental management system across all aspects of daily operations. Additionally, through efficient drug design and clinical development strategies, the Company reduces resource consumption in R&D, advances "green R&D", and achieves synergistic development between innovative research and ecological conservation.



"Patient accessibility" is the Company's core social responsibility. The Company steadfastly fulfills its mission of "providing patients with world-class, trustworthy, and innovative medicines" by actively promoting the inclusion of its products in China's National Reimbursement Drug List to meaningfully reduce patients' financial burden. Simultaneously, it accelerates the global rollout of its products so that Chinese innovation benefits patients worldwide. Going forward, the Company will deepen its public welfare initiatives in rural revitalization, medical aid, and other areas—demonstrating its commitment as a responsible corporate citizen and extending healthcare benefits to broader populations.



The Company consistently upholds compliant operations as a core principle, continuously refines its governance structure, establishes a rigorous compliance system and transparent disclosure mechanisms, and builds a standardized, efficient operational framework. It prioritizes investor rights protection, proactively fulfills disclosure obligations, and strengthens investor engagement—safeguarding the legitimate interests of the Company, shareholders, creditors, and other stakeholders to lay a solid foundation for sustainable development. Additionally, the Company consistently fulfills its responsibilities in employee rights, business ethics, data security, customer service, and supply chain management.

Risk management

The Company prioritizes key ESG topics and has established a comprehensive risk management system spanning environmental, social, and governance dimensions. Through regular identification of potential risks, impact assessments, formulation of response measures, and dynamic optimization of control strategies, it ensures all ESG-related risks remain within acceptable thresholds, thereby safeguarding the Company's sustainable and resilient growth.



Stakeholder Engagement

The Company has established a multi-channel engagement system—both online and offline—to maintain routine dialogue with key stakeholders, including customers, shareholders, government and regulatory agencies, employees, media and the public, suppliers, communities, NGOs, and institutional investors. By deeply understanding their expectations and requirements regarding sustainable development, the Company uses these insights as a critical reference for continuous improvement across all operations.

Stakeholders	Government and regulatory agencies	Shareholders/Investors	Customers/Consumers	Employees	Suppliers/Partners	Community/ Media/Public
Material issues	○ Corporate governance ○ Compliant operation ○ Anti-bribery and anti-corruption ○ Anti-unfair competition ○ Environmental compliance management ○ Pollutant emissions ○ Waste management ○ Water resource utilization ○ Energy utilization ○ Circular economy ○ Climate change response	○ Corporate governance ○ Compliant operation ○ Business ethics ○ Stakeholder engagement	○ Product and service safety and quality ○ Innovation-driven development ○ Technology ethics ○ Data security and customer privacy protection	○ Employee rights ○ Talent training and development ○ Occupational health and safety	○ Supply chain security ○ Industry exchange and cooperation ○ Equal treatment of small and medium-sized enterprises ○ Intellectual property protection ○ Due diligence	○ Social contribution ○ Rural revitalization ○ Inclusive healthcare
Communication channels	○ Conference communication ○ Routine regulatory communication ○ Information disclosure and submission	○ SSE E-interactive Platform ○ General Meeting ○ Periodic reports and announcements ○ Earnings call ○ Investor relations activities ○ Investor emails and hotlines ○ Company's official website and public accounts	○ Routine communication ○ Customer service ○ Quality management ○ Satisfaction management	○ Employee forums ○ Work meetings ○ Employee training ○ Employee activities	○ Supplier management ○ Supplier audit ○ Industry exchange and interaction ○ Routine communication	○ Public welfare activities ○ Charitable donations

Materiality Assessment

01 Establish a sustainable development issue library

- Requirements from regulators, capital markets, and rating agencies;
- Macro-policy and industry standard requirements;
- Peer practices, company business practices, and characteristics.

02 Stakeholder survey

- Gather statistics on issues of concern to stakeholders.

03 Company management survey

- Financial impact analysis of sustainable development issues.

04 Assess materiality


- Assess financial materiality;
- Assess impact materiality;
- Determine the materiality threshold.

05 Form a double materiality matrix

- Form a double materiality matrix to present the results of the issue analysis and assessment.

In compliance with relevant stock exchange regulations, the Company conducted a double materiality assessment—evaluating both the impact materiality (on the economy, society, and environment) and financial materiality of issues—through internal and external stakeholder surveys and industry benchmarking. This process resulted in the 2025 Materiality Matrix, which systematically identified 28 material topics.

Junshi Biosciences 2025 materiality matrix



02

Strengthening Governance Foundations and Upholding Compliance

Junshi Biosciences adheres to the principle of compliant operations, continuously optimizes its corporate governance structure, and builds a standardized and efficient operational system. Guided by accountability, the Company enhances operational efficiency and core competitiveness, effectively safeguards shareholder rights, increases enterprise value, and lays a solid foundation for sustainable development.



16 PEACE, JUSTICE AND STRONG INSTITUTIONS

Corporate Governance

In 2025, the Company continued to enhance its corporate governance structure. In accordance with requirements under laws and regulations including the Company *Law of the People's Republic of China* (hereinafter referred to as the "Company Law"), the *Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange* (hereinafter referred to as the "STAR Market Listing Rules"), and the *Guidelines on the Bylaws of Listed Companies*, and based on its actual operational and management conditions, the Company abolished the Board of Supervisors, with the Audit Committee of the Board of Directors assuming the statutory functions and powers of the Board of Supervisors as stipulated in the Company Law. The *Rules of Procedure for the Board of Supervisors* were accordingly repealed. Concurrently, the Company revised relevant systems, including the Articles of Association of Shanghai Junshi Biosciences Co., Ltd. (hereinafter referred to as the "Articles of Association") and the *Working Rules of the Audit Committee of the Board of Directors*, and dynamically updated its authority and responsibility matrix to ensure the scientific rigor and transparency of corporate decision-making.

The Board of Directors has five specialized committees: the Audit Committee, Nomination Committee, Remuneration and Appraisal Committee, Strategic Committee, and Compliance Committee. Each committee fulfills its deliberative duties on matters such as financial reporting, director appointments, compensation management, strategic planning, and compliance oversight—significantly enhancing the board's operational efficiency, decision-making quality, and supervisory effectiveness, thereby supporting the continuous improvement of the Company's governance framework.

General Meeting

The General Meeting is the Company's highest authority, responsible for making decisions on major corporate matters—including the election and replacement of directors, determination of director remuneration, and approval of the board's reports, profit distribution plans, and general mandates for issuing additional shares. Its convening and voting procedures strictly comply with applicable laws, regulations, and the Company's *Articles of Association*.

Key performance


General Meetings were held

2

Proposals were reviewed and approved by the General Meetings

23

Corporate governance structure



Board of Directors

The Board of Directors is the core institution of the Company's governance system. It strictly implements all resolutions of the General Meeting and is responsible for reviewing and approving the Company's business plans and investment proposals, exercising its operational decision-making authority in accordance with the law. As head of the executive management, the general manager fully implements all board decisions and oversees the Company's day-to-day operations and management.

Requirements of the Company's Board of Directors' independence and diversity policy

Independence

The Company has established the Working System for Independent Non-executive Directors. The qualifications of independent non-executive directors strictly comply with the laws, administrative regulations, listing rules, and other relevant regulatory requirements of the listing jurisdictions, with specific criteria concerning integrity, professional ethics, independence, and professional experience.

Diversity

In accordance with the board diversity policy, the Company selects director candidates based on multiple diversity dimensions, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, expertise, knowledge base, and tenure. Final appointment decisions are primarily based on the candidate's potential to create value and make substantive contributions to board governance.

Internal and external training mechanisms for directors

Internal training for directors

In strict compliance with regulatory requirements for listed companies, the Company regularly organizes systematic training for all directors, covering core topics such as the latest capital market regulations, key compliance points for information disclosure, corporate governance best practices, and insider information management.

External training for directors

The Company coordinates directors' participation in external specialized training sessions organized by securities regulators, stock exchanges, and industry associations, enabling them to stay current with regulatory developments and cutting-edge industry knowledge—continuously enhancing their professional competence and laying a solid foundation for sound, compliant board governance.



The Company's board diversity initiatives

Industry experience

All directors possess extensive industry experience. Core members have worked across multiple domains including new drug R&D, clinical research, manufacturing, commercial operations, capital markets, and compliance. Several directors have held positions at renowned domestic and international pharmaceutical companies, research institutions, healthcare organizations, and investment firms, giving them deep insight into pharmaceutical R&D paradigms, market trends, regulatory requirements, and industry dynamics. This rich collective experience provides a solid foundation for the board's informed decision-making and strategic direction-setting.

Educational background

All directors hold strong academic credentials, with expertise spanning core pharmaceutical disciplines such as pharmacy and clinical medicine, as well as interdisciplinary fields like accounting and business administration. They demonstrate keen judgment and responsiveness to risks across the entire R&D–production–commercialization value chain. Their diverse professional backgrounds and extensive management experience form a robust foundation for the Company's stable operations and high-quality development.

Gender balance

The Nomination Committee reviews the board diversity policy and its implementation annually. When selecting and recommending suitable board candidates, it enhances gender diversity in line with shareholder expectations and operational realities. The Company also plans to promote gender diversity in hiring mid-to-senior-level talent to cultivate a pipeline of potential female successors for senior management and board roles.

Key performance

As of the end of 2025

the Company had **14** board members

including **3** female directors

and **5** independent non-executive directors

In 2025, the Company held **10** board meetings

The average board meeting attendance rate was **100%**

4 board training sessions were conducted

Conducted **4** ESG training sessions

Investor Relations

The Company has always regarded the protection of investor rights as a key priority, conducting its work in strict accordance with laws, regulations, and the relevant provisions of the *Articles of Association*. In 2025, the Company updated and improved its *Investor Relations Management System* based on its actual operational and management conditions, clearly defining the content, methods, organization, and implementation requirements for investor relations management. The Company continuously optimizes its investor relations management mechanism, strengthens communication and engagement with investors, and enhances the professional capabilities and management competencies of relevant personnel through business training. This effectively safeguards the legitimate rights and interests of investors, promotes the establishment of a long-term, stable, and constructive interactive relationship between the Company and investors, and fosters a communication environment characterized by mutual trust and shared value.

The Company treats all investors equitably, avoids selective disclosure, and proactively solicits their opinions and suggestions to enable two-way communication and foster constructive interaction. Primary channels for investor communication include periodic reports and ad-hoc announcements, General Meetings, the Company website, telephone inquiries, the investor relations email address, Q&A on the SSE e-interaction platform, and official social media accounts. The Company also holds earnings briefings, and roadshows, as appropriate, to engage with investors, and the media. Additionally, the Company receives investor visits, phone calls, and email inquiries, actively listens to investor concerns, and upholds their rights and interests.

Key performance

The Company responded to over **60** investor inquiries via the SSE e-interaction platform and SSE Roadshow Center, disclosed **21** voluntary announcements, and published **4** investor relations activity record forms.

The Company held or participated in over **20** investor communication events—including investor conference calls, brokerage strategy conferences, roadshows, reverse roadshows, and corporate site visits—reaching institutional and individual investors both domestically and internationally.

The Company participated in the 2024 Annual Results Briefing for the STAR Market Innovative Drug Sector and the 2025 First Quarterly Results Briefing hosted by the Shanghai Stock Exchange and held its 2025 Interim Results Briefing 2025 Third Quarterly Results Briefing at the SSE Roadshow Center to engage investors in interactive discussions on its operating results and financial metrics.

The Company maintains an investor relations page on its official website to provide a dedicated platform for investor access and mitigate information asymmetry. It also publishes bilingual (Chinese and English) quarterly business reviews, infographic briefings, promotional videos, and earnings news on media platforms to enable investors to gain a more comprehensive and in-depth understanding of the Company's developments.

Transparent disclosure

In accordance with the *Company Law*, the *Securities Law of the People's Republic of China*, the *Rules Governing the Listing of Stocks on the STAR Market*, the *Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited*, and relevant regulatory requirements of the China Securities Regulatory Commission, the Company has established the *Information Disclosure Management System* and revised it in 2025. The system clarifies the fundamental principles, scope, responsible parties, and procedures for information disclosure, aiming to standardize disclosure practices and enhance transparency. The Company consistently adheres strictly to applicable laws, regulations, and internal policies on information disclosure, actively fulfills its disclosure obligations, and effectively safeguards the legitimate rights and interests of the Company, shareholders, creditors, and other stakeholders.

Key performance

In 2025

Disclosed

4 periodic reports

Disclosed

77 ad-hoc announcements



Compliant Operation

Integrity and compliance are core principles underpinning the Company's business development. The Company is deeply committed to cultivating a culture of compliant operations and building a comprehensive, high-standard compliance management system. It strictly complies with national laws, regulations, and pharmaceutical industry regulatory requirements while meeting the internal control and compliance expectations for listed companies. The Company has established a robust internal control framework covering key areas such as fund management, financial reporting, procurement, and fixed asset management, and established the Compliance Committee of the Board of Directors in 2025 to comprehensively strengthen compliance governance.

In 2025, guided by its core values of "Quality First, Truth-seeking, Integrity and Compliance, Pursuit of Excellence", the Company further enhanced its "end-to-end, all-scenario, and all-employee" compliance governance system within the framework of national laws, regulations, and pharmaceutical industry regulatory policies. The Company requires all employees to comply with laws and regulations pertaining to its products or services and to uphold the highest standards of business and personal ethics. In 2025, the Company organized all employees to sign compliance commitment letters and drove a deep transformation from "paper-based commitment" to "actual practice", reinforcing a company-wide foundation of integrity and compliance. Additionally, in line with the requirements of the *Basic Standard for Enterprise Internal Control* (C-SOX), the Company annually conducts enterprise-level and key business-level risk assessments and process matrix reviews to accurately identify critical risk points and implement corresponding control measures.



Main tasks of the Company's compliance management



The Company regularly reviews its internal control system

Internal audit

- One walk-through test per year; two sample testing rounds per year
- Coverage: Junshi Biosciences and its controlled subsidiaries

External audit

- An internal control audit report is issued annually by an accounting firm
- Coverage: Junshi Biosciences and its controlled subsidiaries

Case The Company invited external experts to organize specialized compliance training

In July 2025, the Company invited external compliance experts to deliver the second session of the "Junshi Compliance Lecture Series", covering employees across all roles. The training provided professional instruction on laws and regulations, internal compliance policies, key risk control measures, and illustrative case studies. The content was closely aligned with practical work scenarios and balanced theoretical rigor with applicability. This session strengthened employees' compliance awareness and sense of responsibility, enhanced company-wide capabilities in compliant operations and risk prevention, further standardized internal workflows, reinforced the foundation of compliance management, and ensured that all business activities are conducted in an orderly and compliant manner.



The Company organizes specialized compliance training

Case AI-powered compliance management

To address evolving business and risk management needs, the Company upgraded its compliance governance system through digital and intelligent solutions to enhance quality and efficiency. On one hand, it launched an AI-powered online meeting spot-check system, establishing an integrated digital closed loop for meeting application, approval, execution, spot inspection, and settlement—improving operational efficiency while enabling precise end-to-end compliance control. On the other hand, leveraging its AI assistant "iXiaojun", the Company introduced an intelligent Q&A tool for compliance information, offering employees efficient and standardized compliance advisory services.

In 2025, the Company reinforced its values of integrity and compliance through multi-channel initiatives, including specialized internal control training that engaged 913 participants. It also co-hosted compliance seminars with local regulatory authorities and third-party academic institutions to discuss sustainable development models grounded in policy frameworks, industry standards, and business realities. Through diverse practices—technology enablement, cultural embedding, and external collaboration—the Company has strengthened its compliance governance foundation, providing robust support for sustainable development.



Key performance In 2025

The Company delivered

66 compliance training sessions—encompassing internal controls, anti-bribery, anti-corruption, and anti-unfair competition

and administered

15 compliance assessments

achieving

100% employee coverage

Notably, the internal control and compliance session was conducted **once** and engaged engaged **913** participants.

Business Ethics

The Company places great emphasis on business ethics and fully complies with relevant laws and regulations, including the *Anti-Unfair Competition Law of the People's Republic of China* and the *Interim Provisions on Banning Commercial Bribery*. Through measures such as strengthening institutional frameworks, conducting company-wide compliance training, establishing multi-channel whistleblowing mechanisms, standardizing the management of meetings and business activities, and implementing end-to-end compliance controls, the Company has clearly defined red lines concerning anti-corruption, anti-money laundering, and anti-monopoly, thereby ensuring comprehensive compliance across all operations.

Anti-bribery and anti-corruption

In 2025, the Company fully implemented the compliance philosophy of "zero bribery, zero fraud, and zero tolerance", integrating compliance metrics into the performance evaluation system for all employees to align compliance efforts with business outcomes.



The Company's anti-bribery and anti-corruption measures

Risk identification

Based on differences in job responsibilities, the Company categorizes all employees into four groups: R&D personnel, production personnel, marketing personnel, and logistics support personnel. Considering job functions, external interactions, and levels of authority, the Company ranks commercial bribery and corruption risk from highest to lowest as follows: marketing personnel, R&D personnel, logistics support personnel, and production personnel.

Comprehensive promotion and implementation

The Company organized all employees to take a specialized compliance examination to comprehensively communicate its anti-bribery and anti-corruption requirements. It also initiated thematic seminars, facilitating face-to-face dialogues between senior management and local regulatory authorities to deepen understanding of relevant policies and regulations and drive effective implementation of compliance requirements.

Whistleblower protection

To strengthen compliance oversight, the Company actively encourages employees and all individuals or entities with direct or indirect economic ties to report actual or suspected violations—particularly cases involving employee commercial bribery or corruption—via channels such as email. All reports will be rigorously investigated, and follow-up actions are taken in strict accordance with applicable laws and regulations to ensure serious and appropriate handling of each case.

Upon receiving a report, the Company implements strict confidentiality protocols for whistleblower information, legally protects personal data, and strictly limits access to authorized personnel only. Any investigator who discloses whistleblower information—resulting in adverse impacts or consequences—will be held accountable in accordance with company policies and disciplinary regulations.

Key performance

In 2025



The Company conducted

61 anti-bribery and anti-corruption training sessions



No incidents of commercial bribery or corruption occurred

Categories of personnel participating in anti-bribery and anti-corruption training	Number of people	Coverage
Directors	14	100%
Management personnel	7	100%
Employees	2,903	100%

Anti-unfair competition

To prevent false advertising, the Company established a centralized repository of external promotional materials and implemented a unified management platform to enforce end-to-end control over the application, approval, usage, and validity periods of all promotional content. This ensures all external communications comply with the Company's compliance policies and mitigates false advertising risks at the source. Concurrently, the Company conducts specialized anti-unfair competition training for relevant staff to disseminate knowledge of applicable laws, regulations, and codes of conduct, continuously enhancing company-wide awareness of compliant business practices and supporting a fair and orderly market environment.

Key performance

In 2025

The Company conducted

4 anti-unfair competition training sessions

Anti-unfair competition training reached

2,605 participant instances

No lawsuits or material administrative penalties arose from unfair competition practices

03

Focusing on Patient Needs to Unleash Innovative Momentum

Junshi Biosciences has always remained committed to its founding mission of "focusing on patient needs" and has been deeply engaged in innovative practices within the biopharmaceutical field. Relying on a globally integrated R&D system and a full-chain technology platform, the Company has established a comprehensive layout covering drug discovery, clinical development, and large-scale production. Through cross-departmental collaboration and industry-academia-research innovation, it continuously expands the boundaries of R&D, forming a three-dimensional pipeline encompassing multiple drug modalities and diverse disease areas. At the same time, the Company strictly adheres to quality compliance standards, strengthens data security and customer privacy protections, and enhances supply chain management efficiency. With a robust governance framework and sustained R&D investment, it unleashes innovative momentum to deliver safer, more effective, and more accessible pharmaceutical products and services to patients worldwide.



Product Quality and Service



Quality is the cornerstone of a pharmaceutical enterprise. Junshi Biosciences strictly complies with domestic and international drug regulatory requirements and has established a full life-cycle quality management system centered on the Marketing Authorization Holder (MAH). By refining systems and processes, strengthening company-wide training, and rigorously controlling supply chain quality, it fortifies the defense line for product quality and safety. Simultaneously, it ensures efficient customer feedback channels to safeguard patient health through high-quality products and professional services.

Governance

The Company upholds the quality policy of "Prioritizing Quality, Respecting Life, Keeping Innovation, and Pursuing Excellence". It strictly complies with current domestic regulations, including the *Drug Administration Law of the People's Republic of China*, *Good Clinical Practice* (GCP), *Good Manufacturing Practice* (GMP), and the *Measures for the Reporting and Monitoring of Adverse Drug Reactions*. It also adheres to EU pharmaceutical regulations, the U.S. Code of Federal Regulations, and the tripartite harmonized guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). For newer regulations—including the *Provisions on the Supervision and Administration of the Fulfillment of Medicinal Product Quality and Safety Responsibilities by Holders of Marketing Authorization for Medicinal Products*, the *NMPA Announcement on Strengthening Supervision of Contract Manufacturing by MAHs*, and the *Measures for the Quality Supervision and Administration of the Distribution and Use of Medicinal Products*—the Company has further standardized and enhanced its quality management practices in accordance with relevant requirements.

In accordance with the aforementioned laws and regulations, the Company has formulated the *Quality Manual* (GMP Management System) as its highest-level guiding document for quality management. This manual specifies quality requirements for the quality management system, quality control system, production system, and other areas, as well as the management responsibilities of various quality-related departments. In 2025, the Company optimized and updated the quality manual and key processes such as deviation handling to ensure timely alignment of quality information between the Company and its subsidiaries, supporting operational and production decision-making. Concurrently, it enhanced material supplier management procedures to ensure that suppliers serving subsidiary production are compliant and fulfill contractual obligations effectively. During the reporting period, the Suzhou Wujiang Production Base passed an unannounced inspection for Current Good Manufacturing Practice (cGMP) by the U.S. Food and Drug Administration (FDA). As of the end of the reporting period, both the Suzhou Wujiang and Shanghai Lingang Production Bases had obtained GMP certificates issued by the National Medical Products Administration (NMPA). The Suzhou Wujiang Production Base has received GMP certification and marketing approvals from multiple countries and regions, including China, the United States, the European Union, etc.

Quality training

Each year, in accordance with GMP regulations, the Company conducts regular quality training and assessments for all employees. It also organizes staff to participate in professional training offered by industry organizations and government agencies to continuously deepen their understanding and application of GMP requirements, thereby strengthening the foundation for product quality assurance.

In 2025, the Company conducted a total of 9 GMP regulation training sessions, covering the following topics

- Basic knowledge of GMP regulations
- Good documentation practice
- NMPA GMP Annex – Biological products
- Regulatory considerations for ADC drug CMC studies and GMP inspections
- Regulatory requirements for data integrity
- Basic microbiology knowledge and control of microbial contamination
- Pharmaceutical research and submission requirements for IND applications of innovative biological products



Quality management process

In accordance with drug quality management regulations, the MAH system, and risk control principles, the Company strictly follows NMPA requirements for MAHs and CMOs. It has established a product life-cycle quality management system centered on the MAH, covering the entire process from R&D, production, testing, release, transportation, and sales to post-marketing adverse reaction monitoring and changes.

The Company has established a Corrective Action and Preventive Action (the "CAPA") quality management process, specifying that its sources include deviation handling, product quality reviews, risk assessments, and continuous improvement, with detailed CAPA requirements integrated into relevant management processes. Throughout production, the Quality Control and Quality Assurance departments are fully involved, investigating and testing potential quality and safety issues to verify product compliance with quality standards. Before each batch of finished product is released, it undergoes final review by the Quality Assurance department and may only be marketed upon approval. For marketed products, the Company conducts annual quality reviews to assess key elements such as quality testing indicators, complaints, non-conformities, and deviations, and implements corresponding improvement measures to continuously enhance product quality.

Product recall management

The Company has formulated the *Product Recall* procedure, which specifies requirements for information collection, decision-making, planning, implementation, reporting, and mock recalls during drug recall activities. This enables investigation and evaluation of potential quality issues or other safety hazards and ensures prompt recall of affected products. During the reporting period, the Company had no product recall incidents.

Product recall process

Discovery of quality issue or hazard → Investigation and assessment → Issue reporting → Recall decision → Recall initiation → Recall implementation → Recall closure

This process sets clear time limits and expected outcomes for key steps throughout the recall process to ensure efficient and timely execution of product recall actions;
If no product recall occurs in a given year, the Company conducts a mock recall drill every two years to ensure the effectiveness and operability of the recall process.

Customer service

The Company values customer service and feedback and actively builds channels for customer engagement. It has established the *Standard Operating Procedures for Customer Complaint Management* and the *Standard Operating Procedures for Management of Adverse Reactions of Drugs*, and has implemented an adverse reaction monitoring system to track customer experiences with its products.



Strategy

Risk type	Specific description	Impact period*	Response measures
Product production	Ensuring quality consistency across different production lines and batches.	Long-term	Involvement of quality control throughout production and pre-testing to mitigate risks; finished products are released only after passing final inspection, and annual quality reviews are conducted for marketed products with continuous optimization.
Safety monitoring	Delays in collecting and analyzing adverse events may postpone risk identification, leading to regulatory and trust crises.	Long-term	A Drug Safety Department has been established to regularly retrieve and process scientific literature, prepare safety update reports, and evaluate and manage safety signals and risks, thereby strengthening drug safety defenses across multiple dimensions.
Service response	Failure to monitor adverse reactions promptly may reduce patient compliance and satisfaction and damage brand reputation.	Short- and medium-term	An adverse reaction monitoring system is in place to track product use experience. Drug safety issues must be reported through multiple channels within 24 hours. The Drug Safety Department handles information processing and assessment, follow-up, and regulatory and partner reporting as required.

Opportunity type	Specific description	Impact period	Response measures
Green pharmacy	Improve production efficiency and quality while meeting increasingly stringent environmental requirements.	Medium- and long-term	Optimize process flows and reduce energy consumption and waste.

Drug safety training

The Company's Drug Safety Department manages drug safety information both pre- and post-marketing, covering the full lifecycle of individual case safety reports and related information. Sources include, but are not limited to, the adverse event reporting page on the Company's official website, the Drug Safety Department's public email, hotline, scientific literature, social media, and verbal reports. The processing workflow includes receipt, registration, data entry, review, medical assessment, submission of domestic and international reports, follow-up, and handling of special cases. In compliance with domestic and international regulations, the department regularly retrieves and processes scientific literature, prepares and submits Periodic Safety Update Reports (PSURs), and evaluates and manages safety signals and risks. The Company uses the Oracle Argus Safety pharmacovigilance database, and the pharmacovigilance lead has authorized access to ensure comprehensive oversight of all drug safety information.

In accordance with the Company's *Safety Information Reporting Responsibilities for Spontaneous Reporting Sources*, the Drug Safety Department delivers annual updated training on safety information reporting responsibilities to all employees. In 2025, company-wide training was launched in January, covering pharmacovigilance responsibilities and employees' duty to report relevant information to the Drug Safety Department in their daily work.

* Considering the business characteristics of Junshi Biosciences, which focuses on innovative R&D, and the pace of its project advancement, in this report, short-term refers to within 1 year after the end of the reporting period, mainly corresponding to the annual operational and expense management cycle; medium-term refers to 1–3 years after the end of the reporting period, mainly corresponding to the period when improvements in R&D efficiency, process optimization, and compliance management effects gradually become apparent; long-term refers to more than 3 years after the end of the reporting period, mainly corresponding to the period of asset layout, changes in cost structure, and the formation of long-term competitiveness.

Impact, risk, and opportunity management

The Company has a dedicated Drug Safety Department staffed with full-time pharmacovigilance personnel responsible for monitoring, identifying, assessing, and controlling adverse drug reactions and other drug-related harmful reactions to fully protect the safety of clinical trial participants/patients. The Company requires employees, partners, and third parties acting on its behalf to report any drug safety information they become aware of within 24 hours via the hotline, the adverse event reporting page on the official website, or the Drug Safety Department's public email. The department promptly processes and assesses all received safety information, follows up on missing or critical details, and submits compliant individual case safety reports to relevant regulatory authorities and domestic and international partners on schedule.

In 2025, the Company's pharmacovigilance system enhanced procedures for creating, reviewing, approving, distributing, withdrawing, and maintaining procedural documents in accordance with the *Lifecycle Management of Procedural Documents*. This covers work protocols and requirements for all drug safety activities, and relevant staff must complete training before commencing duties. During the reporting period, the Company passed a specialized pharmacovigilance inspection conducted by the Shanghai Drug and Medical Device Adverse Reaction Monitoring Center.

For death events, mass adverse events, or cluster events occurring in Chinese mainland, the Company has established a special investigation mechanism and will complete and submit investigation reports to the relevant drug regulatory authorities and adverse reaction monitoring institutions as required.


君实生物
TopAlliance

欢迎来到药品安全性信息报告页面

根据相关法规规定，药品上市许可持有人有责任和义务收集收集药品使用过程中的疑似药品不良反应信息，并根据实际情况向国家监管机构报告。根据法律要求，药品上市许可持有人在药物安全数据库中进行数据处理时，一切能够识别您个人身份的信息将被保护。

药品安全性信息包括不良事件及特殊情况。不良事件是指任何发生在患者的不利的医学事件。它并不一定同药物治疗有因果关系。不良事件可以是一种不利的、与用药目的无关的体征（也包括异常的实验室检查等）、症状或疾病，与药物 使用有时间相关性，不考虑是否同药物有因果关系。特殊情况是指可能不符合不良事件的定义，但是它们需要被收集以满足法规部门的要求，包括：妊娠暴露、哺乳期暴露、缺乏疗效、超说明书用药、用药错误、药物误用、药物滥用、职业暴露、药物过量、非预期获益/疗效、药物相互作用、产品质量投诉、质量问题（包括假药，劣药等）、通过产品传播感染性病原体、现有疾病的进展、复发和恶化。

医疗专业人士

非医疗专业人士

君实生物员工

请选择一种符合您身份的选项：

Adverse event reporting page on the official website

Indicators and targets

Number of product recalls

0 case

Product recall rate

0%

Amount of damages involved in major liability accidents related to product service safety and quality

0 yuan

Number of product quality improvement training sessions held

17 sessions

Total duration of product quality improvement training

14,000 hours

Number of people covered by product quality improvement training

803 persons

Pharmacovigilance marketing training coverage rate

100%

Total number of people trained in pharmacovigilance*

3,011 persons

* This figure is based on data from the Company's Training Management System (TMS) and includes former employees.

Data Security and Customer Privacy

The Company complies with relevant laws and regulations, including the *Cybersecurity Law of the People's Republic of China and the Personal Information Protection Lawof the People's Republic of China*, and has established policies such as the *Data Classification and Grading Management Specification* and the *Data Security Management Specification*. Additionally, it has formed an information security working group led by the Information Technology Department, with collaborative participation from Legal, Human Resources, and Compliance functions. This group provides multi-dimensional support for data security and privacy protection, covering compliance management, legal requirements, security strategies, technical safeguards, and human resources. During the reporting period, the Company obtained certification for its information security management system and experienced no data security or customer privacy breaches.


DNV

管理体系认证证书

上海君实生物医药科技股份有限公司

ISO/IEC 27001:2022标准

ISO27001:2022 certificate

Data security and customer privacy protection management process

Classification and grading

Data is systematically classified and graded based on sensitivity and business impact, enabling differentiated and stricter protection measures for critical data to achieve refined security controls.

Partners

A risk management mechanism for external partners is established throughout the cooperation lifecycle:

Prior to engagement, security capability due diligence is conducted via questionnaires, interviews, and on-site assessments, followed by signing a Non-disclosure Agreement.

During cooperation, ongoing oversight is maintained through regular audits, personal information Protection Impact Assessments (PIAs), and cross-border data risk assessments to ensure continuous compliance with the Company's data security standards.

Recovery system

A systematic data backup and disaster recovery management system is in place. Full-process disaster recovery drills are conducted regularly to continuously validate the effectiveness of recovery procedures and the integrity of backup data, ensuring rapid business restoration and continuity in the event of emergencies.

Information security and privacy protection measures

Strengthen layered network defense	Deploy next-generation firewalls (NGFW) and traffic threat detection platforms to enable real-time monitoring and automated blocking of anomalous network-layer behavior, effectively mitigating external threats.
Enforce strict perimeter and access controls	Minimize internet-facing exposure, implement Privileged Access Management (PAM) and the principle of least privilege, and enforce mandatory authentication and full auditing for access to critical zones.
Enhance the security management system	Systematically optimize information security documentation and processes to continuously strengthen integrated capabilities in data security governance, risk assessment, and compliance management.
Implement end-to-end data encryption	Apply AES-256 or stronger encryption for data at rest and enforce TLS 1.2 or higher for data in transit to ensure security throughout the data lifecycle.

In 2025, the Company delivered multiple information security training sessions, including clinical data security and awareness enhancement, and reinforced company-wide security consciousness through regular communications. Online information security awareness training reached 1,037 participant instances.



Information security awareness training exam

Customer privacy protection

The Company places high priority on protecting customer rights, actively establishing diverse communication channels, and has formulated the standard operating procedures for *Interaction and Communication with External Institutions and Personnel*, which clearly defines privacy and confidentiality boundaries and requirements. Business personnel are required to strictly adhere to these protocols. The Compliance Department reinforces routine supervision and maintains a "zero tolerance" stance toward privacy breaches, ensuring prompt and serious action upon detection to safeguard customer rights.

Supply Chain Management



Supply chain security is a critical foundation for the stable development of pharmaceutical enterprises. The Company implements full life-cycle supply chain management, strictly complying with relevant laws and regulations, and standardizes the entire supplier lifecycle—from admission, evaluation, audit and exit—through formalized policies. Guided by the principle of transparent procurement, it strengthens compliance and quality controls, conducts risk assessments, and deepens collaboration with high-quality suppliers to reinforce supply chain resilience and reliably support R&D and manufacturing.

Governance

The Company has developed and implemented a core supply chain management system. The *Supplier Management Policy* defines standardized procedures for the entire supplier life cycle. The *Supplier and Procurement Management* framework establishes standardized operating procedures to regulate all procurement activities. The Procurement and Supplier Management Center oversees supplier admission reviews, performance evaluations, and relationship management. The Quality Management Center conducts quality audits and compliance oversight for GMP material and service suppliers. These two centers collaborate closely to jointly advance ESG risk assessments and capacity-building initiatives for suppliers.

Strategy

In supplier management, the Company strictly complies with laws such as the *Bidding Law of the People's Republic of China* and the *Drug Administration Law*, implementing closed-loop, full life-cycle management. For GMP suppliers, it rigorously fulfills its MAH responsibilities by establishing *Supplier Management* and *Supplier Audit* procedures, conducting risk-based classification and assessment, and defining end-to-end management requirements and operational protocols for supplier selection, evaluation, utilization, suspension, and exit.

Additionally, the Company applies differentiated audit frequencies and methodologies based on supplier categories. Audits cover core dimensions including authenticity of qualification documents, personnel and organizational structure, facilities and equipment, supply chain and production management, quality control, data reliability, and sterility assurance. Audit findings are categorized and addressed through targeted corrective actions.

Supplier management process

Supplier classification

HCO category: Academic associations/foundations, hospitals/research institutions

General supplier category: Marketing, engineering, GMP, R&D, others

Supplier admission

Priority: Existing supplier pool resources are prioritized; new suppliers require evaluation.

Criteria: Suppliers must hold valid qualifications and requisite supply capabilities, and meet category-specific admission standards (e.g., GMP suppliers require quality department approval).

Evaluation and audit

General suppliers: Annual performance evaluation for the prior year is conducted in Q1, covering delivery, cost, KPI/KQI, and other dimensions.

Specialized suppliers: Regular evaluations for GMP suppliers; pre-admission and in-cooperation audits for clinically critical categories.

High-risk, high-expenditure suppliers: Contract execution audits conducted as needed.

Exit mechanism

Suspension: No business for 24 months, failure to meet standards after rectification (without material impact), etc.; re-admission possible later.

Disqualification: Material impact after suspension, legal/regulatory violations, or serious compliance failures; no re-admission permitted.



Transparent procurement

The Company requires all procurement staff to sign an *Employee Integrity Commitment Letter* upon onboarding. All suppliers must sign a *Supplier Integrity Commitment Letter* upon admission, explicitly pledging to eliminate bribery, improper benefit transfers, and fraud, adhering to standardized gift and hospitality policies, and agreeing to cooperate with company audits and investigations.

Compliance verification is conducted through two procedures:

- Review anti-corruption training records and whistleblowing mechanisms during due diligence;
- Search public sources for any commercial bribery-related litigation or administrative penalties. Violators are subject to measures ranging from warnings and cooperation suspension to termination, depending on severity.



Risk type	Specific description	Impact period	Response measures
Compliance risks	Expired supplier credentials, GMP/GCP violations, integrity breaches, etc.	Short- and medium-term	Strengthen admission due diligence and periodic audits.
Quality risks	Non-compliant materials/services from suppliers may compromise R&D/production compliance.	Medium- and long-term	Implement closed-loop, full life-cycle supplier management with category-specific audits covering qualifications, personnel, equipment, management, and quality. Audit findings are graded and addressed with tailored corrective actions.

Opportunity type	Specific description	Impact period	Response measures
Cooperation opportunities	Collaborate with technologically advanced and high-performing suppliers in the industry.	Medium- and long-term	Identify opportunities through supplier technical exchanges and industry forums.

Impact, risk, and opportunity management

The Company conducts supplier risk assessments per established procedures and leverages technical exchanges and industry forums to identify collaboration opportunities in areas such as continuous manufacturing and traceability technologies, comprehensively evaluating their potential value and feasibility in cost reduction, efficiency gains, product differentiation, and brand enhancement.

Equal treatment of small and medium-sized enterprises

The Company adheres to fair competition and non-discriminatory principles, establishing transparent and standardized cooperation mechanisms across supplier admission, partnership evaluation, and transaction negotiations. It strictly honors payment terms and standardizes settlement processes. During the reporting period, there were no overdue payments, effectively protecting the rights of small and medium-sized enterprises and contributing to a collaborative, win-win, stable, and healthy industrial ecosystem.

Indicators and targets

The Company has set quantifiable targets for external due diligence. In 2025, it completed external due diligence on 104 general suppliers and 188 association-type suppliers, effectively implementing data-driven management requirements.

Number of suppliers

2,011

Number of domestic suppliers

1,849



Innovation-driven Development


Innovation is the core competitiveness of biopharmaceutical enterprises. Guided by unmet clinical needs, the Company has built a globally integrated R&D system and a full-chain technology platform. Leveraging a multi-center collaborative model and a high-caliber R&D team, it continuously expands its R&D frontiers across diverse drug modalities and disease areas. Through robust management systems, specialized training, and innovation incentive mechanisms, it empowers its R&D teams to achieve efficient breakthroughs, consistently fueling momentum in pharmaceutical innovation.

Governance


The Company's core R&D strength is rooted in its globally integrated R&D system. It has established two central R&D units—the Innovation Research Institute and the Clinical R&D Department—to holistically advance the entire R&D continuum, from drug discovery and process development to preclinical research and clinical trials. By operating R&D centers in Maryland (USA), Suzhou and Shanghai (China) under a collaborative division-of-labor model, it effectively enhances R&D efficiency and reduces costs.

The Innovation Research Institute comprises a Drug Discovery Department, a Preclinical Pharmacology Department, and a CMC Development Department, coordinating the full R&D chain from drug discovery and process development to preclinical research and clinical trials. Core R&D team members largely have backgrounds from leading research institutions and multinational pharmaceutical companies in China and abroad, bringing deep expertise and extensive hands-on experience. The Drug Discovery Department focuses on emerging trends in innovative therapeutics and leads new target identification, candidate assessment, and in vitro/in vivo testing. The Preclinical Pharmacology Department validates the safety and efficacy of drug molecules through laboratory and animal studies, providing the foundation for clinical trials. The CMC Development Department manages subsequent stages, overseeing drug process, formulation, and analytical method development, as well as technology transfer and scale-up studies. The U.S. laboratory primarily supports international clinical trials with analytical testing and comparability studies, underpinning the Company's global R&D footprint.

R&D management structure



Additionally, the Company has established standard policies including the *R&D Project Lifecycle Management Procedure*, *R&D Team Management Procedure*, and *R&D Project Centralized Review Meeting Management Procedure* to clarify departmental responsibilities, standardize R&D workflows and communication mechanisms, and effectively enhance R&D project management efficiency. During the reporting period, the Company was recognized as a "Specialized, Refined, Unique, and Innovative" SME in Shanghai.


附件
2025年上海市专精特新中小企业（第二批）名单

List of "Specialized, Refined, Unique, and Innovative" SMEs in Shanghai

R&D training

In terms of training, the Innovation Research Institute organized multiple specialized training sessions in 2025, covering both preclinical and clinical R&D. The preclinical R&D training focused on key issues and solutions at various development stages of innovative antibody drugs, as well as key CMC considerations at different stages of biotech new drug R&D. The clinical R&D training centered on a basic introduction to and key considerations in clinical trial design for anti-tumor drugs, and key considerations in the clinical development of drugs for chronic diseases. Additionally, AI experts were invited to deliver GxP regulation-related AI module training to help R&D personnel enhance their understanding and application of AI tools.

Technology ethics

The Company strictly adheres to industry standards and conducts preclinical efficacy and toxicology studies in professionally qualified experimental institutions. All research protocols are submitted to the Ethics Committee for rigorous review in advance and implemented only after approval. The entire experimental process is carried out by qualified professionals and subject to comprehensive oversight by the Ethics Committee. In experimental design, the Company scientifically determines experimental groups and animal numbers, meeting the minimum quantity requirements stipulated in guidelines while fully aligning with the 3R principles of "Reduction, Replacement, and Refinement". This ensures scientific validity and reliability of the research while maximizing animal welfare. During the reporting period, the Company had no incidents involving violations of science and technology ethics.

The Company's measures for complying with science and technology ethics

- The Innovation Research Institute has established a comprehensive R&D quality management system to ensure data authenticity and traceability. It has formulated the *Good Documentation Practice Management Procedures* and *Computerized System Validation and Data Standards Management Procedures*, requiring R&D records to comply with applicable regulations and ICH guidelines and mandating that the entire data lifecycle adhere to ALCOA+ principles. An Electronic Lab Notebook (ELN) has been introduced to replace paper-based records, mitigating risks such as inconsistent templates and loss of documentation. Standardized handling processes for deviations, changes, CAPA, and OOS/OOT/OOE have been established to ensure compliance of the quality system.
- Preclinical efficacy and toxicology studies are conducted through qualified experimental institutions. Research protocols are reviewed and approved by the Ethics Committee and executed by professional personnel under full supervision. Experimental group allocation and animal numbers strictly comply with the minimum requirements of relevant guidelines and fully implement the 3R principles.
- A risk assessment has been completed for biological raw materials such as genetically recombinant mammalian cells, and a full-chain biosafety management system has been established. This includes conducting safety training for personnel, standardizing sample receipt, storage, and management by designated staff, inactivating biological waste before handing it over to qualified third-party disposal providers, equipping laboratories with appropriate personal protective equipment and providing usage training, and implementing annual health check plans for laboratory personnel.

Strategy

Risk type	Specific description	Impact period	Response measures
Innovation risk	The drug proves ineffective or causes serious adverse effects during the preclinical or clinical trial stage.	Long-term	Diversified pipeline portfolio; enhanced early-stage screening and validation; strengthened clinical evaluation.
Cost risk	High R&D investment and long development cycles result in significant financial pressure.	Long-term	Enhance commercialization capabilities while strengthening cost control and resource prioritization; improve self-sustaining capacity.

Opportunity type	Specific description	Impact period	Response measures
Policy opportunities	The government encourages innovative drug R&D and provides support such as priority review and inclusion in medical insurance reimbursement programs.	Medium- and long-term	Closely follow policy directions; promote the inclusion of approved products and indications in the National Reimbursement Drug List.

The Company has assembled a high-caliber R&D team and collaborates with industry-leading enterprises, focusing on unmet clinical needs globally. The R&D team is highly experienced, with core members drawn from renowned domestic and international research institutions and multinational pharmaceutical companies, possessing solid theoretical and practical foundations. The Company has established an R&D center in the United States to absorb advanced overseas technologies and enhance its R&D capabilities. Its R&D scope has expanded from initial monoclonal antibody drugs to include small molecule drugs, antibody-drug conjugates (ADCs), bispecific or multispecific antibody drugs, fusion proteins, nucleic acid-based therapeutics, vaccines, and the exploration of next-generation innovative therapies for cancer and autoimmune diseases, gradually evolving into an innovative pharmaceutical company with a multi-dimensional and diversified R&D system.

In 2025, the Company's R&D investment reached RMB 1.342 billion, primarily directed toward early-stage R&D and clinical trials of innovative drugs, providing solid support for the rapid advancement of its pipeline. As of the end of the reporting period, the Company had four commercialized drugs (TUOYI®, JUNMAIKANG, MINDEWEI, and JUNSHIDA), several products in Phase III clinical studies or marketing application stage, and multiple innovative drugs with international market competitiveness undergoing accelerated clinical trials.



Key Projects Entering the Clinical R&D Stage (As of 13 March 2026)

Phase I/II		Phase III	Approval for marketing
JS213 PD-1 x IL-2	**JS207** PD-1 x VEGF	**Tifcemalimab** BTLA	Toripalimab PD-1
JS212 EGFR x HER3 ADC	**JS015** DKK1	**JS001sc** PD-1	Adalimumab TNF-a
JS007 CTLA-4	**JS203** CD20 x CD3	**JS105** PI3K-a	Deuremidevir Hydrobromide Tablets RdRp
JS214 VEGF x TGF-β	**JS110** XPO1	**JS107** Claudin18.2 ADC	Ongericimab PCSK9
JS111 EGFR 3rd GEN	**JT002** small nucleic acid immunomodulator	Roconkibart IL-17A	

.....

○ Oncology ● Metabolism

● Immunology ● Infectious disease

R&D achievements

In 2025, the Company responded to unmet clinical needs with innovative breakthroughs, achieving a series of key advancements across several core R&D areas:

In January 2025, the indication for the core product toripalimab (TUOYI®) for the treatment of unresectable or metastatic melanoma in patients who have failed prior systemic therapy was converted by the National Medical Products Administration (NMPA) from conditional to full approval. In March 2025, the NMPA approved the supplemental New Drug Application (sNDA) for TUOYI® in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma. In April 2025, the NMPA approved the sNDA for TUOYI® for the first-line treatment of unresectable or metastatic melanoma. In August 2025, the NMPA accepted the sNDA for TUOYI® in combination with disitamab vedotin for first-line treatment of HER2-expressing urothelial carcinoma. As of the end of the reporting period, all 12 approved indications for TUOYI® in Chinese mainland have been included in the National Reimbursement Drug List, making it the only anti-PD-1 monoclonal antibody in the list indicated for renal cell carcinoma, triple-negative breast cancer, and melanoma.

In May 2025, the NMPA approved two new indications for ongericimab injection (recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA): 1) for adult patients with heterozygous familial hypercholesterolemia (HeFH); and 2) for adult patients with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or for whom statins are contraindicated, either as monotherapy or in combination with ezetimibe. Ongericimab became the first domestically developed PCSK9-targeted drug approved for use in statin-intolerant patients. Additionally, in 2025, JUNSHIDA was included in the National Reimbursement Drug List for the first time — making it the only domesic PCSK9-targeted drug for statin-intolerant patients under the new edition of the National Reimbursement Drug List.

In September 2025, JS005 (Roconkibart injection, recombinant humanized anti-IL-17A monoclonal antibody injection) achieved positive results in a multi-center, randomized, double-blind, parallel and placebo-controlled pivotal registrational Phase III clinical study for moderate-to-severe plaque psoriasis. The NMPA has accepted the New Drug Application for JS005 for the treatment of adult patients with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy.

In November 2025, a multi-center, open-label, randomized, controlled Phase III clinical study comparing JS001sc (toripalimab subcutaneous injection) versus TUOYI® plus chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer met its primary endpoint. As of the date of this report, the new drug applications for JS001sc for 12 indications for the treatment of tumors (representing all of Tuoyi®'s currently approved indications in Chinese Mainland) has been officially accepted by the National Medical Products Administration.

A multi-center, randomized, placebo-controlled, open-label phase III clinical study of anti-Claudin18.2 ADC (JS107) comparing the efficacy and safety of treatment of physician's choice for the second-line or later treatment of Claudin18.2 positive advanced gastric or gastro-oesophageal junction cancer is underway . As of the end of the reporting period, the Company had multiple products in Phase III clinical trials or marketing application stage.

Driven by innovation, the Company is actively advancing its leading pipeline and rapidly progressing clinical trials of multiple innovative drugs with international competitiveness, including a PD-1/VEGF bispecific antibody (JS207), an EGFR/HER3 ADC (JS212), and a PD-1/IL-2 fusion protein (JS213). The Company is also actively exploring various combination regimens to maximize pipeline synergy. Clinical trial applications for JS207 and JS212 were successively approved by the U.S. FDA in October 2025 and December 2025, enabling Chinese innovative solutions to embark on global exploration in cutting-edge fields.

In 2025, the Company achieved abundant academic accomplishments, with frequent highlights from its core products and multiple innovative pipelines. Together with Chinese experts, the Company presented over 135 research findings at international academic forums such as ASCO, WCLC, and ESMO, showcasing progress across diverse therapeutic areas through oral presentations, posters, and other formats. Over 200 research reports were published in top-tier international journals including *The New England Journal of Medicine* and *The Journal of the American Medical Association*, comprehensively demonstrating the Company's robust scientific innovation capabilities and global academic influence.


Academic conferences

In February 2025

Multiple studies on toripalimab were selected for oral and poster presentations at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), with a focus on perioperative treatment of urological tumors involving various combination strategies.

In March 2025

The latest data from a Phase I/II study of tifcemalimab combined with toripalimab for previously treated advanced lung cancer (Study No.: JS004-006-I/II-LC) were selected for an oral presentation in the Lung Cancer session of the Presidential Session at the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO) 2025.



In May 2025

At the 105th Annual Meeting of the American Association for Thoracic Surgery (AATS) 2025, the Phase III NEOTORCH study of toripalimab plus chemotherapy for perioperative treatment of resectable stage II–III non-small cell lung cancer was selected for an oral presentation.

In April 2025

At the American Association for Cancer Research (AACR) Annual Meeting 2025, clinical study results from multiple innovative pipelines were presented, covering novel therapies such as bispecific antibodies and ADCs. Among them, Phase I clinical data for JS107 (anti-Claudin18.2 ADC) in advanced solid tumors were presented orally for the first time; early clinical data for JS015 (anti-DKK1 monoclonal antibody) in gastrointestinal tumors were disclosed for the first time as a Late-Breaking Research poster; and Phase I clinical data for JS203 (CD20×CD3 bispecific antibody) in hematologic malignancies were displayed as a poster.

In May 2025

At the European Society for Radiotherapy and Oncology (ESTRO) 2025 Congress, a Phase II study of toripalimab combined with radiotherapy as neoadjuvant therapy for esophageal squamous cell carcinoma was selected for a Proffered Paper oral presentation.

In June 2025

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, a total of 30 research findings on toripalimab were selected, including five oral presentations—two of which were Late-Breaking Abstract (LBA) oral presentations—and over 20 posters and abstracts, covering multiple areas including head and neck/nasopharyngeal cancer, lung cancer, breast cancer, gastrointestinal tumors, urologic cancers, gynecologic cancers, melanoma, and sarcoma, demonstrating the strength of its diverse and innovative combinations.

In June 2025

A Phase Ib/II clinical study of JS005 (anti-IL-17A monoclonal antibody) for the treatment of patients with moderate-to-severe psoriasis (PsO) was selected as a Late Breaking Research presentation at the 30th Annual Meeting of Chinese Society of Dermatology (CSD 2025), with detailed results shared via an oral presentation.

In September 2025

At the 21st World Congress of the International Society for Diseases of the Esophagus (ISDE 2025), the latest safety data from the Phase III HCHTOG1909 study of toripalimab for perioperative treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) were announced in an oral presentation.

In September 2025

At the 28th National Congress on Clinical Oncology and the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), multiple research findings on toripalimab were selected, showcasing the latest results in urologic cancers, colorectal cancer, and breast cancer through oral presentations, posters, and other formats.

In September 2025


At the 2025 World Conference on Lung Cancer (WCLC), the latest clinical evidence for the anti-BTLA monoclonal antibody tifcemalimab plus anti-PD-1 dual immunotherapy for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), and results from a Phase II randomized controlled study comparing toripalimab consolidation therapy versus observation alone after concurrent chemoradiotherapy (CCRT) in patients with limited-stage small cell lung cancer (LS-SCLC), were selected for oral presentations

In November 2025

At the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 2025, the latest results from the overseas Phase I clinical study of JS213 (a PD-1/IL-2 bifunctional fusion protein) were announced.

In October 2025

At the 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO) 2025, five research findings on toripalimab were selected for oral and poster presentations, presenting the latest cutting-edge academic results on integrated treatment strategies such as radiotherapy combined with toripalimab in digestive system tumors, renal cell carcinoma, cervical cancer, and nasopharyngeal carcinoma.



In November 2025

At the European Society for Medical Oncology (ESMO) Congress 2025, over 20 studies on toripalimab, tifcemalimab, and JS105 (a PI3K-α inhibitor) were presented.

In December 2025

At the 67th American Society of Hematology (ASH) Annual Meeting 2025, the latest clinical study results for JS203 (an anti-CD20/CD3 bispecific antibody) and JS110 (an XPO1 inhibitor) were announced.

In December 2025

At the European Society for Medical Oncology Asia Congress 2025 (ESMO ASIA 2025), the latest clinical study results for multiple innovative products—including toripalimab, JS107 (an anti-Claudin18.2 ADC), and JS207 (a PD-1/VEGF bispecific antibody)—were announced. Among them, JS107 was selected as a Late-Breaking Abstract (LBA), and Phase I clinical trial data for JS207 were presented for the first time.

Journal publications

In January 2025

The latest three-year long-term follow-up data from a Phase Ib/II study of toripalimab combined with disitamab vedotin for locally advanced or metastatic urothelial carcinoma were published in *Annals of Oncology* (IF:65.4).

In February 2025

Results from a Phase Ib/II clinical study of the anti-LAG-3 monoclonal antibody (LBL-007) combined with the anti-PD-1 monoclonal antibody (toripalimab) for advanced solid tumors were published in *Journal of Hematology & Oncology* (IF:40.4).

Results from a Phase III clinical study of ongericimab for adult patients with HeFH were published in *Atherosclerosis*.

In March 2025

The full research results for JS005 (anti-IL-17A monoclonal antibody) were published in *Acta Dermato-Venereologica*, a leading international dermatology journal.

In April 2025

Results from a Phase II study of neoadjuvant toripalimab triplet therapy for locally advanced penile squamous cell carcinoma were published in *Cancer Cell* (IF:44.5).

In April 2025

Results from a clinical study of neoadjuvant toripalimab combined with chemotherapy plus concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma were published in *eClinicalMedicine* (IF:10.0), a journal of *The Lancet*.

In May 2025

Results from the Phase III HEPATORCH study of toripalimab combined with bevacizumab (TB regimen) for first-line treatment of advanced hepatocellular carcinoma (HCC) were published in *The Lancet Gastroenterology & Hepatology* (IF:38.6).

Full data from a Phase I first-in-human (FIH) clinical study of tifcemalimab (anti-BTLA monoclonal antibody) as monotherapy or in combination with toripalimab for patients with relapsed or refractory (R/R) lymphoma were published in *Nature Communications* (IF:15.7).

In June 2025

Full data from a Phase I/II clinical study of tifcemalimab combined with toripalimab for patients with EGFR- or ALK-negative advanced non-small cell lung cancer (NSCLC) and refractory extensive-stage small cell lung cancer (ES-SCLC) who had failed prior standard therapies were published in *Clinical Cancer Research* (IF:10.2).

In June 2025

Frontiers in Immunology published the full article on the anti-tumor mechanism of action and preclinical study results of JS207 (PD-1×VEGF bispecific antibody), detailing its molecular design, in vitro characteristics, functional properties, and preclinical anti-tumor efficacy.

Complete results from a Phase III clinical study (Study No.: JS002-007) of ongericimab for primary hypercholesterolemia and mixed dyslipidemia in statin-intolerant patients were published in *Atherosclerosis*, the official journal of the European Atherosclerosis Society (EAS), marking the first disclosure of lipid-lowering efficacy and safety data for ongericimab in a Chinese statin-intolerant population.

In August 2025

The Phase III DIAMOND study of toripalimab combined with induction chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma was published in *The Journal of the American Medical Association* (JAMA, IF:55.0).

In October 2025

Breakthrough results from the world's first Phase III clinical study of a combination therapy using an anti-PD-1 monoclonal antibody (toripalimab) and an anti-HER2 ADC for urothelial carcinoma were published in *The New England Journal of Medicine* (NEJM, IF:78.5).

Team empowerment

The Company has strengthened its early-stage research team by conducting in-depth investigations in key disease areas and completing target evaluations and project initiations throughout the year. While steadily achieving milestones across R&D projects, the Company actively promotes lean management in R&D and manufacturing. Artificial intelligence technologies have been introduced to empower process optimization and cost control. To date, domestic process substitution studies for multiple projects have been completed, reducing production material costs by over 40% and simultaneously achieving increased output and reduced costs. The Company continues to refine and optimize its proprietary culture media formulations, with successful implementation across multiple projects. Additionally, multiple AI platform tools and technologies have been deployed to enhance work efficiency, assist in document drafting and translation, and support core R&D activities such as drug discovery, screening, and evaluation.

Innovation incentives

The Company has established a comprehensive performance appraisal and incentive system to stimulate the innovative drive and work motivation of its R&D team. At the beginning of 2025, personalized performance goals were set for R&D personnel based on performance metrics and behavioral values. In the middle of the year, department heads conducted performance review discussions with employees. At the end of the year, a comprehensive annual performance evaluation was completed, and employees with outstanding performance were awarded the title of "Excellent Employee" along with rewards. Additionally, the Company has implemented project-specific incentives: individuals who excel when R&D projects reach key milestones—such as IND acceptance or marketing approval—are recognized as "Project Stars" and rewarded accordingly. Furthermore, an equity incentive plan has been launched, covering core R&D personnel and management.

Industry chain advantages

The Company's operations span the entire value chain of innovative drugs—from early discovery and global clinical development to large-scale manufacturing and commercialization—supported by a robust R&D, procurement, production, and sales system. It has also built a technology platform covering the full lifecycle of protein therapeutics, from early R&D to industrialization. On this foundation, the Company has established a globally integrated R&D process. The Drug Discovery Department of the Innovation Research Institute is responsible for initial high-throughput antibody screening, as well as antibody humanization, selection, and optimization. Leveraging a membrane receptor proteome library and a eukaryotic cell functional assay platform, the department conducts novel target identification and candidate antibody evaluation. The two major production bases in Wujiang, Suzhou, and Lingang, Shanghai—supported technically by the Innovation Research Institute—undertake core functions including stable cell bank establishment, process optimization, GMP-compliant production, global quality system implementation and maintenance, and the production of clinical trial materials and commercial products.

In terms of international expansion, the Company adheres to a "China-rooted, global-reaching" strategy. Its core product, toripalimab, has been approved for marketing in over 40 countries and regions, including China, the United States, the European Union, etc., and is under regulatory review in multiple countries and regions worldwide.


Indicators and targets

R&D expenditure

1,342.1232 million yuan

Number of R&D personnel

640 persons



Proportion of R&D personnel to total company employees

22.05%

Intellectual Property Protection



Intellectual property is the cornerstone of pharmaceutical innovation. The Company places high priority on protecting its innovative achievements and has established an IP management system covering all business scenarios. In accordance with relevant laws and regulations, it has formulated and regularly updates policies for patents, trademarks, and other IP assets. The Intellectual Property Department oversees the entire IP lifecycle, building a robust innovation "moat" through multi-dimensional strategies including patent portfolio development, trademark protection, and trade secret controls.

Governance

The Company attaches great importance to IP protection. In compliance with the *Patent Law of the People's Republic of China*, its *Implementing Regulations*, and the *Patent Examination Guidelines*, it has established a *Patent Management System* and supporting implementation measures to systematically standardize the entire patent management process, effectively safeguarding the innovative achievements of the Company and its partners, and implementing a life-cycle patent strategy for pharmaceutical products. Regarding trademark management, in accordance with the *Trademark Law of the People's Republic of China*, the Company simultaneously advances domestic filings and international trademark portfolio development. While proactively filing applications, it continuously monitors the market for similar trademark usage. After registration, the Intellectual Property Department actively monitors for potential infringements and uses a systematic approach to manage trademark renewals.

In 2025, the Company updated its *Intellectual Property Management Specification*, which applies to comprehensive IP management across all departments and subsidiaries, covering scientific research and technology development, brand and marketing operations, clinical R&D, manufacturing and process improvement of pharmaceuticals, external collaborative R&D and technology transfer, as well as IP-related confidentiality, authorization, licensing, assignment, and enforcement activities.

The Company's Intellectual Property Department coordinates end-to-end IP management. With clearly defined internal roles and responsibilities, dedicated personnel handle strategic IP planning, patent searching, analysis, filing, and maintenance, as well as IP-related process management and support functions. Additionally, the Company conducts targeted IP training aligned with business development needs, offering tiered instruction for R&D teams on patent searching, claim interpretation, design-around strategies, and patent filing and portfolio-building approaches, thereby establishing a solid foundation for protecting the Company's innovations.

Strategy

Risk type	Specific description	Impact period	Response measures
Legal risks	Technology being imitated or misappropriated.	Medium- and long-term	Conduct regular market monitoring; promptly collect evidence and take legal action upon detecting infringement.

Opportunity type	Specific description	Impact period	Response measures
Competitive advantages	Establish a "moat" through patent portfolios and trade secrets to raise competitors' entry barriers and costs.	Long-term	Implement a multi-layered, integrated IP strategy around core technologies (covering molecules, processes, formulations, and combination therapies).

Impact, risk, and opportunity management

The Company's Intellectual Property Department is responsible for formulating and implementing the IP strategy, establishing an IP risk management system to mitigate related risks, and coordinating patent mining, application, portfolio development, and management. While proactively filing trademark applications, the department continuously monitors market usage of similar marks. After registration, it actively screens for infringement and manages the entire trademark renewal process through a systematic approach to ensure continued validity of trademark rights. Regarding employee confidentiality, the Company requires core employees to sign confidentiality agreements upon hire, clearly stipulating ownership of subsequently generated IP. R&D personnel with access to technical information sign additional technical confidentiality agreements to strengthen protection of core technical information and clarify IP ownership.

Indicators and targets

As of the end of the reporting period, the Company held 193 granted patents, including 134 in China and 59 overseas, covering novel drug protein sequences, manufacturing processes, therapeutic uses, and formulation compositions, providing comprehensive patent protection across the product life cycle.

Number of patents held

193 cases

Number of invention patents held

88 cases

Number of newly granted patents during the year

19 cases

Number of patents under examination

291 cases

Number of copyrights held

10 cases

Number of trademarks held

177 cases

04

Fulfilling Environmental Responsibilities to Protect Our Green Home

Junshi Biosciences is committed to the philosophy of green development, integrating environmental responsibility throughout its entire production and operation process. Guided by regulatory compliance, energy conservation, carbon reduction, and green development, the Company has established a comprehensive management system covering environmental compliance, resource utilization, and pollutant disposal. Through technological optimization, process control, and full employee participation, it promotes the implementation of green R&D and low-carbon operations, contributing to the sustainable development of the ecological environment while ensuring compliant operations.





Environmental Compliance Management

The Company adheres to the resource utilization policy of "conserving resources and controlling pollution, complying with laws and regulations, continuous improvement, and green development", systematically integrating environmental compliance requirements into production, operations, and daily management activities. To fulfill environmental management responsibilities, the Company has formulated and implemented management documents including the *Environmental Management Manual*, *Environmental Self-Monitoring Management System*, and *Hidden Environmental Risk Identification and Rectification System*. These documents standardize processes for identifying environmental factors, monitoring and control, risk investigation, and corrective action implementation, thereby strengthening the foundation of environmental compliance management. The Shanghai Lingang Production Base and the Suzhou Wujiang Production Base have both obtained ISO 14001 environmental management system certification, promoting the institutionalized and procedural implementation of environmental management requirements in production operations and continuously enhancing the standardization and effectiveness of environmental management.



ISO14001 environmental management system certification for Suzhou Wujiang Production Base



ISO14001 environmental management system certification for Shanghai Lingang Production Base

In line with its production characteristics, the Company systematically identifies potential environmental impact factors arising from its production and operational activities, compiles a list of significant environmental factors, and establishes a mechanism for regular inspections and dynamic updates to continuously monitor key environmental risk points. For major risks such as hazardous chemicals and hazardous waste, the Company has developed and continuously improves environmental emergency response plans for incidents like chemical spills and hazardous waste leaks. It regularly conducts emergency drills to enhance its response capabilities and disposal efficiency for sudden environmental events, thereby reducing the potential impact of environmental risks on production, operational activities, and the surrounding environment.

In 2025, the Shanghai Lingang Production Base prepared and filed the *Environmental Risk Assessment Report* and the *Emergency Response Plan for Environmental Emergencies*. The Halei Road Laboratory simultaneously updated and re-filed its environmental emergency response plan, improving relevant environmental risk identification and management measures, and organized environmental emergency drills to continuously enhance its response capabilities for sudden environmental events and reduce the potential impact on production, operational activities, and the surrounding environment.



Case **Environmental emergency drill**

In March 2025, the Company organized an environmental emergency drill for laboratory staff, focusing on hazardous waste leakage, to enhance rapid response and standardized disposal capabilities for sudden environmental events. The drill simulated a hazardous waste leakage scenario in the laboratory, where staff strictly followed the preset procedures: Step one was to quickly isolate the leaked hazardous waste and delineate a safety zone to prevent the spill from spreading; step two was to evenly spray disinfectant in the leakage area to reduce environmental risks; step three was to use specialized tools to properly collect the leaked waste, ensuring no residue remained; and step four was to thoroughly clean the leakage area to restore site cleanliness. Throughout the drill, the laboratory head provided on-site command and coordinated all stages of the work.

After the drill, the person in charge organized an on-site summary and training session to help staff further consolidate their emergency response skills and strengthen their awareness of environmental safety.





Environmental emergency drill at the Halei Road Laboratory

The Company anchors its core goal of "green, low-carbon, and compliant operations" and has established a full-chain environmental risk prevention and control system encompassing "policy communication, system improvement, collaborative implementation, self-inspection and rectification, and practical validation". During the reporting period, the Company successfully passed supervisory inspections by environmental protection authorities at all levels, with no serious environmental incidents or administrative penalties.

In 2025

Invested a total of **4.9903** million yuan in environmental protection

Conducted **11** environmental management training sessions

Recorded **0** violations of environmental laws and regulations

Incurred **0** yuan in significant administrative penalties imposed by ecological and environmental authorities for environmental incidents during the reporting period

Environmental management goals for the Shanghai Lingang Production Base

Environmentally compliant operations, zero environmental accidents, and zero environmental administrative penalties.

Resource and Energy Utilization

In its resource and energy management, the Company strictly complies with laws and regulations such as the *Energy Conservation Law of the People's Republic of China*. In line with its actual production and operations, the Company continuously advances energy conservation, consumption reduction, and efficient resource utilization through institutional regulations, system support, and operational management improvements, which provides a management basis and execution guidance for low-carbon and stable operations.

Energy management

Relying on its energy management system, the Company continuously monitors and assesses energy usage. In qualified production sites, it promotes the use of clean energy, optimizes the energy consumption structure, and improves operational management. In 2025, the Company implemented a photovoltaic power generation project, substituting part of its electricity consumption with clean energy, which generated over 10,000 kWh from September to December. Concurrently, by replacing natural gas boilers with piped steam, it optimized the energy supply structure, reducing emissions of pollutants such as nitrogen oxides and sulfur dioxide. Furthermore, by optimizing the operating parameters of lighting and air conditioning systems and configuring energy storage facilities, the Company enhanced the economic efficiency and operational stability of its energy use.

Energy-saving measures

- Actively respond to the demands of the power system, adjusting electricity consumption behavior and patterns as required, avoiding peak-hour usage, and implementing economical electricity consumption methods;
- Regularly maintain production equipment and promptly replace components as needed to ensure production efficiency and safety;
- Replace natural gas boilers with piped steam to reduce emissions of nitrogen oxides and sulfur oxides;
- Install solar photovoltaic power generation systems to substitute part of the electricity consumption with clean energy;
- Continuously replace lighting systems with smart lighting, with an estimated annual electricity saving of over 16,000 kWh;
- Implement frequency reduction adjustments for the high-bay warehouse air conditioning system, saving 58,000 kWh of electricity annually.

Each production base implements energy-saving management requirements based on its own operational characteristics. The Suzhou Wujiang Production Base conducts quarterly energy consumption analysis and control to continuously reduce unnecessary energy use. The Shanghai Lingang Production Base focuses on energy conservation and consumption reduction through equipment and system upgrades, implementing projects such as replacing boilers with piped steam and installing rooftop photovoltaics, thereby driving the transition of production operations toward a green and low-carbon model.

The Company emphasizes capacity construction to ensure the long-term effectiveness of its energy management efforts. It organizes professional training in energy management for relevant personnel to enhance their understanding and execution of energy statistics analysis, operational optimization, and energy-saving management requirements. During the reporting period, two employees from the Shanghai Lingang Production Base participated in energy management training and obtained relevant certificates.



In 2025

Consumed a total of **10,377.38** tce in energy

Achieved an energy use intensity of **4.15** tce per million yuan in revenue

Consumed **1,841.18** tce of direct energy consumption

Including

Gasoline **74.24** tonnes

Diesel **10,159.65** liters

Consumed **8,536.2** tce of indirect energy consumption

Including

Electricity **35,656.63** MWh

Clean energy **11,412** kWh

Water resource management

The Company focuses on the rational use and recycling of water resources in its production and operations. Relying on its energy and resource management system, it continuously monitors and evaluates water usage. Each production base promotes water conservation and reuse measures based on its specific process flows and operating conditions, reducing reliance on fresh water resources.

At the Shanghai Lingang Production Base, the Company has implemented a steam condensate recovery project. The recovered water is used as make-up water for cooling towers, which not only meets production needs but also improves water use efficiency and expands scenarios for resource recycling.

Case **Recovery and cascade utilization of steam system condensate**

The Shanghai Lingang Production Base has implemented a steam condensate recovery and utilization project to centrally collect and reuse the condensate generated during the operation of the steam pipe network. The recovered condensate passes through a heat exchange device, where part of its residual heat is used for the air conditioning system, reducing the system's energy consumption. After cooling, the water is further used as make-up water for cooling towers and intermediate water tanks, replacing some of the fresh water intake. Through this project, the Company has achieved cascade energy utilization and water resource recycling, saving approximately 180 tonnes of water per day. This ensures stable production operations while effectively improving resource use efficiency.



Water conservation initiatives

- Establishing a water usage recording system to monitor and document water consumption during production;
- Installing additional secondary and tertiary water meters, based on the existing Building Management System (BMS) and energy management system, to achieve more precise classified statistics for electricity and water consumption;
- Conducting regular inspections and maintenance of the water supply system, increasing the frequency of patrols, strengthening the detection and repair of leaks, and posting water-saving slogans, to reduce unnecessary water loss;
- Continuously advancing the reclaimed water reuse project, using reclaimed water for watering plants and flushing toilets on company premises.

In 2025

Consumed a total of **191,220** tonnes of water

Achieved a water consumption intensity of **76.54** tonnes per million yuan in revenue

Water conservation targets

Shanghai Lingang Production Base

In 2025, the Company set a goal to reduce the water use intensity at the Shanghai Lingang Production Base by 2% compared to 2024. The actual water consumption per ten thousand yuan of output value was 5.154 tonnes, a decrease of 8.7% from 2024, significantly outperforming the annual target. Tap water consumption was 306,459 tonnes, a reduction of 12,850 tonnes or 4% from 2024.

Suzhou Wujiang Production Base

In 2025, the Company set a goal to reduce water consumption by 15 tonnes compared to 2024. The actual reduction was approximately 20 tonnes, surpassing the water-saving target.



Green office

In its daily operations, the Company continuously promotes the concept of a green office, integrating resource conservation and waste reduction into office management and employee conduct. By promoting electronic documents and online meetings, it is progressively reducing the use of paper documents and paper consumption. It also encourages the recycling of office supplies to extend their lifespan and improve resource use efficiency.

To achieve its energy-saving and emission-reduction goals, the Company raises employee awareness of conservation by posting promotional slogans and issuing management notices. It advocates for green office habits such as double-sided printing, rational electricity use, and proper air conditioner usage, while also promoting the recycling of waste paper for resource reuse. For business travel, the Company rationally plans routes for official vehicles and optimizes vehicle management to reduce energy consumption and carbon emissions, continuously minimizing the environmental impact of its office operations.

Pollutant and Waste Management

The Company strictly complies with laws and regulations such as the *Environmental Protection Law of the People's Republic of China*, the *Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution*, and the *Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste*. In line with its actual production and business operations, it has formulated and implemented internal management systems, including the *General Waste Management System*, the *Pollutant Prevention, Control, and Discharge Management System*, and the *Solid Waste Management System*. These systems specify requirements for pollutant prevention and control, classified waste disposal, and operational management, thereby mitigating the potential impact of its production and business activities on employee health, surrounding communities, and the environment.

The Company has established a dedicated department for environmental protection, safety, and occupational health, with professionally experienced EHS personnel responsible for pollutant and waste management. It commissions qualified third-party testing agencies to regularly monitor wastewater, waste gas, and noise levels at the plant boundary to ensure all pollutants are consistently discharged in compliance with standards. Additionally, the Company conducts regular inspections of waste gas treatment facilities and wastewater collection and treatment facilities to promptly identify and rectify potential hazards, ensuring the continuous and stable operation of environmental protection equipment. During the reporting period, the Company did not receive any major administrative penalties or face criminal liability for pollutant emissions. The existing environmental monitoring program and risk management measures are operating normally, with no major deficiencies identified.

Waste gas management

The Company's R&D, production, and experimental processes mainly generate organic waste gas and bioaerosols from microbial experiments. It adopts a management approach of classified collection and differentiated treatment for different types of waste gas to ensure effective purification before discharge. Organic waste gas from experimental activities is collected through fume hoods and a centralized area extraction system, then purified by an activated carbon adsorption device before unified discharge. Bioaerosols are filtered through the built-in HEPA filtration system of safety cabinets for internal circulation, with filter components replaced regularly. The Company also continuously strengthens laboratory ventilation management to mitigate related environmental risks. During the reporting period, the Company had no instances of exceeding waste gas emission standards. The emission data for waste gas were far below the maximum allowable emission concentrations and rates stipulated by various standards.

In 2025

Nitrogen oxide (NO_x) emissions


0.079 tonnes

Sulfur oxide (SO_x) emissions

0.003 tonnes

Volatile organic compounds (VOCs)

0.061 tonnes



Wastewater management

The Company's wastewater primarily includes cleaning wastewater, sterilizer wastewater, tailwater from purified water systems, and domestic sewage from employees. The concentrations of relevant pollutants in the discharged wastewater comply with the limits specified in the *Pollutant Discharge Standard for the Biopharmaceutical Industry* (DB31/373-2010) and the *Integrated Wastewater Discharge Standard* (DB31/199-2018). After classified collection, the wastewater is uniformly discharged into the municipal sewage network for centralized treatment at a sewage treatment plant. Wastewater from the quality inspection laboratory and biofilter, among others, is pre-treated in the Company's self-built wastewater treatment facility before discharge to ensure that both water quality and quantity meet the standards for compliant discharge.

In 2025

Discharged a total of
120,107 tonnes of wastewater

Chemical oxygen demand (COD)
7.84 tonnes

Ammonia nitrogen (NH_3-N)
0.41 tonnes

Wastewater management goals

Shanghai Lingang Production Base

In 2025, wastewater generation was 218,098 tonnes, a 3.7% decrease compared to 2024.

Suzhou Wujiang Production Base

In 2025, the goal of achieving compliant wastewater discharge was set and successfully met.

Waste management

The waste generated by the Company's production and laboratory activities is mainly divided into two categories: general solid waste and hazardous waste. General solid waste includes activated sludge, inorganic waste, waste molecular sieves, waste plastics, waste glass, and domestic waste. Hazardous waste mainly includes waste chemical liquids from laboratories, scrapped pharmaceuticals, waste activated carbon, waste disposable shake flasks, waste disposable reactors, waste filters, waste ion-exchange resins, waste packaging materials, non-conforming products, and solid waste from laboratories.

In 2025, the Company updated the *Solid Waste Management System* to further refine the storage and disposal requirements for general solid waste and supplement the management standards for liquid hazardous waste storage containers, continuously improving the level of waste classification management and standardized disposal. Relying on the continuous improvement of the system and management practices, the Shanghai Lingang Production Base has consistently achieved its goal of reducing waste generation intensity by 5%. During the reporting period, it was awarded the title of "Waste-Free Factory" as part of the "Waste-Free Cell" initiative in the Lingang New Area for 2024, reflecting the Company's phased achievements in promoting source reduction, standardized management, and resource utilization.

General solid waste management

The Company implements classified management for different types of general solid waste in accordance with the principles of classified collection, standardized storage, and compliant disposal. It uniformly entrusts qualified third-party disposal units to carry out harmless treatment, ensuring that the disposal process is standardized, safe, and traceable.

The Company actively promotes green office practices by reducing resource consumption through paperless office, double-sided printing, recycling of office supplies, and waste paper collection. It advances packaging reduction by selecting green and environmentally friendly packaging materials and strictly controlling material balance to reduce packaging waste. Meanwhile, it optimizes production processes by adopting measures such as activated sludge stabilization treatment and source process improvements to effectively control waste generation and practice green, low-carbon production.

In 2025, the achievements in general solid waste reduction were as follows

Shanghai Lingang Production Base: The solid waste generation intensity was reduced from 0.41 tonnes/10,000 boxes to 0.29 tonnes/10,000 boxes.



Hazardous waste management

The Company standardizes the management processes of the collection, storage, transfer, and disposal for hazardous waste. Hazardous waste generated from the production system and quality inspection workshops is collected centrally, placed in dedicated sterilization containers, and after high-temperature sterilization, temporarily stored in a hazardous waste temporary storage room. It is then regularly handed over to professional institutions holding hazardous waste operation licenses for collection and disposal.

In daily operations, the Company strengthens on-site control and personnel protection requirements for hazardous waste management. Laboratories and production workshops are equipped with dedicated collection containers based on the nature of the waste, which are clearly labeled and placed at designated points. Hazardous waste is transferred by designated personnel wearing protective equipment at specified times and along prescribed routes. Hazardous waste storage facilities are kept well-ventilated and clean, with classified management and ledger records maintained to minimize potential environmental and safety risks during storage and transportation. In 2025, all hazardous waste was properly disposed of in compliance with regulations.

In 2025, the achievements in hazardous waste reduction were as follows

Shanghai Lingang Production Base: The hazardous waste generation intensity was reduced from 0.48 tonnes/10,000 boxes to 0.40 tonnes/10,000 boxes.

Noise management

Suzhou Wujiang Production Base, strictly complies with Category 3 standards of the *Emission Standard for Industrial Enterprises Noise at Boundary* to regulate noise emission management at its plant boundaries. It enhances the environmental compliance awareness of all employees by promoting noise management regulations and requirements. In the project design and equipment procurement stages, low-noise equipment is prioritized, the plant layout is optimized, and vibration damping and sound insulation measures are implemented to control noise at the source. Additionally, routine maintenance of production and auxiliary equipment is strengthened to reduce abnormal equipment noise. The Company commissions third-party noise monitoring annually to ensure compliance with emission standards, effectively safeguarding the tranquility and stability of the surrounding environment. In 2025, Suzhou Wujiang Production Base achieved 100% compliance in noise emissions.

In 2025

Generated a total of **187.1** tonnes of non-hazardous (general) solid waste

Recorded a non-hazardous (general) solid waste intensity of **0.075** tonnes per million yuan in revenue

Generated a total of **232.06** tonnes of hazardous solid waste

Recorded a hazardous solid waste intensity of **0.093** tonnes per million yuan in revenue

Achieved a hazardous solid waste compliant disposal rate of **100%**

Addressing Climate Change

The Company pays attention to the impacts of climate change, actively responds to the national dual-carbon strategy, and aligns with international climate governance consensus such as the *Paris Agreement*, integrating climate change response into its corporate management. With reference to the Task Force on Climate-related Financial Disclosures (TCFD) framework, the Company advances climate-related management and information disclosure, continuously enhancing its governance standardization and transparency.

Governance

Board of Directors

Responsible for overseeing climate change-related risks and opportunities and reviewing their impact on the Company's strategy and operations; supervising executive departments in implementing climate-related initiatives and regularly tracking progress; ensuring alignment with the national "dual carbon" goals and ESG governance requirements, and assuming ultimate responsibility for the formulation and implementation of climate change management policies and strategies.

EHS department

Responsible for the specific implementation of environmental compliance management, energy conservation, and emission reduction practices; formulating and executing specific measures to address climate change (such as risk prevention and control, and emergency plans); and assisting the Board of Directors in tracking and reporting progress on climate-related goals to ensure the compliant implementation of all climate actions.

Strategy

The Company has identified physical and transition risks related to climate change based on its business characteristics and assessed their potential impact on R&D activities, operating costs, and business stability. On this basis, it has formulated corresponding response measures from the perspectives of operational management and resource allocation, incorporating relevant risks and opportunities into daily management and decision-making. The table below lists the main climate-related risks and opportunities identified by the Company and the corresponding response measures.

Risk type		Specific description	Response measures	Impact period
Physical risks	Acute risks	The increasing frequency and intensity of extreme weather events may cause temporary disruptions to production, laboratory operations, or cold chain logistics, leading to additional expenses for equipment repair, emergency response, and alternative transportation, and may also cause delivery delays, resulting in cash flow fluctuations.	Enhance extreme weather emergency plans and response procedures, strengthen disaster resilience and operational continuity of critical facilities, and reinforce emergency coordination mechanisms across the supply chain and logistics.	Medium- and long-term
	Chronic risks	Climate change trends such as sustained high temperatures may increase cooling demand in laboratories, production, and warehousing, leading to higher electricity consumption, which in turn raises operating costs and squeezes profit margins.	Promote energy-saving retrofits and operational optimization, improve the efficiency of cooling and energy-consuming equipment, and strengthen refined energy management.	Medium-term
Transition risks	Policy and regulatory risks	Stricter environmental and carbon-related regulations may raise compliance and management requirements, leading to increased investment in system implementation, monitoring, and remediation, thereby exerting pressure on operating cost structures and capital expenditure planning.	Continuously monitor policy developments, enhance environmental and energy management systems and processes, and strengthen compliance management capabilities and execution quality.	Medium- and long-term
	Technology risks	Accelerated iteration of low-carbon and energy-efficient technologies may place the Company at a disadvantage in meeting energy efficiency and compliance requirements if capacity building is insufficient, necessitating increased R&D investment or technology upgrade expenditures in the short term and affecting periodic cash flow planning.	Advance technological optimization and digital applications in R&D and operations, moderately replace energy-consuming equipment and optimize processes to improve resource utilization efficiency.	Medium-term
Opportunity type		**Specific description**	**Response measures**	**Impact period**
R&D efficiency opportunities		The use of virtual screening technology in R&D—simulating interactions between drug molecules and targets via AI algorithms—reduces the number of experiments and shortens the R&D cycle, thereby lowering laboratory energy consumption and R&D costs, enhancing the efficiency of R&D investment and improving cash flow turnover.	Introduce AI technology for novel target identification, refine evaluation mechanisms and application standards, and drive cost reduction and efficiency gains in R&D.	Medium-term
Resource efficiency opportunities		By adopting energy-efficient equipment and green chemistry processes in laboratories and leveraging online analytics and data visualization to enhance resource efficiency, the Company can gradually reduce unit costs in R&D and testing, improve its expense structure, and increase profit contribution.	Promote the adoption of energy-efficient equipment and the implementation of green chemistry processes, and enhance the use of tools such as online analytics and data visualization in optimizing R&D workflows.	Medium-term
Operational management opportunities		Measures such as economical electricity use, promotion of green office practices, and adoption of environmentally friendly packaging materials can reduce daily operating expenses and material consumption, positively influencing period expense control.	Optimize electricity management and office operation standards, promote green procurement and substitution of packaging materials, and institutionalize green office practices.	Medium-term
Long-term competitiveness opportunities		Continuously integrating low-carbon principles into R&D and operational management helps reduce long-term business uncertainty, stabilize cost structures and profit expectations, and enhance the Company's long-term resilience and sustainable operational capacity.	Continuously advance low-carbon management practices and capacity building, and progressively integrate climate considerations into business management and risk identification processes.	Long-term

Impact, risk, and opportunity management

The Company fully recognizes the impacts of climate-related risks and opportunities and has integrated climate risk management into its enterprise-wide risk management framework. In its strategic planning and business development, it comprehensively considers climate-related risks and opportunities, clarifies long-term goals and vision under the context of climate change, and formulates a specific climate strategy. The EHS department identifies, analyzes, and assesses climate-related risks and opportunities, and—based on the Company's actual business operations—develops a climate response strategy, defines relevant indicators, and establishes targets and action plans.

Management objective

Clarify the primary categories of climate change management—namely physical risks, transition risks, and opportunities—and establish the Company's climate management objectives based on identification outcomes to ensure targeted and effective management actions.

Assess risks/opportunities

Identify a comprehensive list of the Company's climate-related risks and opportunities, assess their impact severity, prioritize them accordingly, and identify key climate-related risks and opportunities.

Analyze impact

Review the Company's response measures for each key risk and opportunity, and conduct financial and other analyses to comprehensively evaluate the impacts of addressing these climate-related risks and opportunities on the Company.

Response measures

Building on prior findings, review and refine the Company's response measures for each key risk and opportunity, and integrate them into a climate change management pathway to inform future climate risk management and target setting.

Indicators and targets

In 2025

Emitted

3,039.21 tonnes of CO_2 equivalent

under Scope 1 greenhouse gas emissions

Emitted

32,311.55 tonnes of CO_2 equivalent

under Scope 2 greenhouse gas emissions

Reported total greenhouse gas emissions of

35,350.76 tonnes of CO_2 equivalent

Circular Economy

The Company focuses on efficient and circular use of resources throughout its production and operations, integrating circular economy principles into key areas such as packaging and water resource management. In packaging management, it adopts eco-design principles, prioritizes renewable and environmentally friendly raw materials, and collaborates with packaging suppliers holding industry-recognized green credentials. During packaging operations, the Company sets clear controls on packaging material utilization rates and, upon completion, conducts material balance calculations for all packaging types and records results accurately to minimize waste and enhance the standardization and controllability of resource use.

In water resource management, the Company promotes reclaimed water reuse by treating and repurposing recoverable water from production and operations for appropriate applications—subject to safety and regulatory compliance—thereby reducing freshwater intake, improving water use efficiency, and supporting systematic resource recycling.

In 2025

Consumed

22.88 tonnes of packaging materials used for finished products



05

Safeguarding Life and Health and Undertaking Social Responsibility

Junshi Biosciences remains steadfast in its patient-centered mission, deeply embedding social responsibility into its corporate DNA. Focusing on core areas including equitable healthcare access, employee well-being, and societal contribution, the Company fulfills its corporate citizenship through diverse initiatives—such as improving access to innovative medicines, supporting primary healthcare, safeguarding employee rights, and nurturing talent. It continuously expands the scope of its social engagement, responding to societal expectations through concrete actions to advance health equity and sustainable social development.



Employee Rights

The Company consistently prioritizes employee rights protection by refining end-to-end systems covering equal employment, compensation and benefits, and democratic communication, complemented by diverse employee care and talent attraction initiatives, thereby fostering a fair and equitable environment for employment and career development and achieving mutual growth and shared success for employees and the enterprise.


Governance

The Company has established an employee governance system centered on the Board of Directors with cross-departmental collaboration. The Remuneration and Appraisal Committee of the Board evaluates the Company's compensation system and reviews its implementation. The Human Resources Department oversees recruitment, training, and performance management. The Legal and Intellectual Property Department and Group Compliance Department ensure that company and employee conduct complies with laws and regulations. Business units implement day-to-day management and on-the-job training. The labor union, as the employee representative body, participates in democratic consultation and rights-related dialogue to jointly foster harmonious labor relations. Through institutionalized operations and regular feedback mechanisms, the Company provides robust support for employee rights protection and career development, enabling synergistic progress between employees and the enterprise.


Number of employees

2,903 persons


Number and proportion of employees by gender




Number and proportion of employees by employment type




Number and proportion of employees by age



Number of employees by rank



Number of employees by work region



Equal employment

The Company strictly complies with national labor laws and regulations and firmly upholds core principles of equal opportunity, diversity and inclusion, non-discrimination, and the prohibition of child labor and forced labor. During recruitment, the Human Resources Department and hiring units review candidate qualifications to ensure compliance with legal requirements and company policies. Candidates found to have provided false information or violated regulations will not be hired; current employees engaging in fraud or misconduct will be disciplined in accordance with the *Employee Misconduct Management Measures*.

The Company continuously enhances its policy framework covering recruitment, attendance, leave, and separation. By implementing current standards such as the *Recruitment Management System* and *Attendance and Leave Management System*, it ensures transparent and fair recruitment and legally compliant attendance and leave management. In 2025, the Company further revised the *Employee Departure and Handover Management Guidelines* to optimize offboarding procedures and work handover mechanisms, comprehensively strengthening the foundation for employee rights protection.

During onboarding, the Company systematically delivers training on employee rights and compliance. All new hires are required to study the *Employee Handbook*, which covers core topics including fundamental employee rights, anti-workplace sexual harassment policies, occupational health and safety standards, and information security protocols—enabling them to fully understand company policies, their rights, and expected conduct, and laying the groundwork for smooth integration into the workplace.

Talent attraction

Guided by the talent philosophy of "integrity first, professionalism as the foundation, pragmatism and initiative, and mutual growth", the Company continuously refines its talent acquisition system and adheres to the "global vision + local execution" staffing principle, building core teams by integrating overseas experts and local talent to strengthen its talent base. In talent development, it implements a tiered, systematic cultivation program spanning from new hire onboarding to high-potential talent participation in international project execution, comprehensively enhancing talent capabilities.

In 2025, based on channels including campus recruitment, social hiring, and internal/external referrals, the Company deepened its campus engagement by hosting 46 autumn recruitment events across multiple leading universities. It actively collaborated with university career services to strengthen school-enterprise partnerships and align talent needs, enhancing youth talent attraction effectiveness. Concurrently, the Company maintained focus on critical roles and continuously refined its recruitment strategies to deliver precise and sustainable talent support for business growth.

Democratic communication

The Company values employee participation in democratic management. In accordance with the *Company Law*, the *Trade Union Law of the People's Republic of China*, and the *Regulations on the Congress of Workers and Staff*, following the principles of democratic participation, equal dialogue, transparency, and balanced consideration of business operations and employee interests, it has established a democratic management mechanism centered on the trade union and workers' congress. Major matters affecting employee rights are reviewed by the workers' congress, which provides opinions and recommendations. Additionally, the Company maintains systems such as regular forums and engagement surveys, ensuring open communication channels and robust oversight mechanisms to effectively collect and respond to employee feedback, fostering a culture of collective contribution and shared benefits.



Strategy

Opportunity type	Specific description	Impact period	Response measures
T-shaped talent development	The industry urgently demands "T-shaped talent" with cross-disciplinary integration capabilities. Through systematic training programs, the Company builds differentiated talent competitiveness.	Long-term	Deepen the training system by strengthening professional knowledge and leadership development—particularly non-positional influence for cross-functional collaboration—to generate more successful internal collaboration and win-win cases. Enhance regulatory update training, introduce interdisciplinary skills courses, and accelerate leadership pipeline development by engaging high-potential talent in international project execution.
Industry-education integration	School-enterprise collaboration strengthens talent development—enriching the talent pipeline, enhancing organizational vitality, and providing employees with sustainable career pathways.	Long-term	Expand university partnerships through joint R&D talent cultivation, co-established internship bases, and other formats; allocate dedicated funding for talent development to build a reserve of specialized professionals.

Impact, risk, and opportunity management

The Company has built a risk and opportunity management system centered on employee rights, covering the full employee lifecycle from recruitment through employment to separation, to foster mutual growth between employees and the enterprise. Recognizing the biopharmaceutical industry's talent intensity and stringent compliance requirements, it systematically identifies key risks—including core talent retention, compensation competitiveness, and compliant employment—through industry benchmarking, employee surveys, and regulatory tracking, while also seizing opportunities in organizational effectiveness and benefits optimization. A tiered control mechanism is in place: risks are mitigated through policy revisions (e.g., *Employee Performance Management System*, *Recruitment Management System*), process optimization, and increased resource allocation, while opportunities are converted into targeted improvement initiatives. Feedback is gathered via performance appeals and employee dialogue channels, and management effectiveness is continuously monitored using metrics such as turnover rate and social security coverage, with regular reviews and dynamic strategy adjustments.

Indicators and targets

Ethnic minority

Number of ethnic minority employees

112 persons

Protection of basic rights and interests*

Employee social insurance coverage rate

99.24%

* Excluding rehired retirees and foreign nationals, social security contributions cover 100% of all other employees.



Talent Development

The Company has established a diversified employee value empowerment system—enhancing capabilities through an improved training framework and integration of high-quality internal and external resources; supporting career progression through a competitive compensation, benefits, and promotion structure; and reinforcing its talent foundation by implementing employee care initiatives and safeguarding employee rights and well-being—to achieve mutual growth between the Company and its employees.

Training and development

Viewing employees' growth as a cornerstone of corporate development, the Company has formulated the *Operating Procedures for New Employee Training Preparation and Execution*, comprehensively covering knowledge and skill development from onboarding through on-the-job stages to ensure employees are qualified for their roles after completing pre-employment training and assessment. Supported by the *Training Management Measures*, the Company provides a policy foundation for employees to access continuous, business-aligned training resources, enabling steady professional advancement and career progression.

The Company has developed a comprehensive training system comprising three core modules tailored to employees' evolving developmental needs. New hire training focuses on essential knowledge and skills to accelerate cultural assimilation and workplace integration. Professional and technical training is business-driven, ensuring role readiness and regulatory compliance through continuous updates on regulations and reinforced procedural and hands-on training. In leadership and general capability development, management jointly formulated the *Junshi Biosciences Management Covenant* in 2025 to systematically standardize leadership behaviors. Additionally, the Company conducts needs assessments and team workshops at the employee level to deliver customized training programs, which have received positive feedback.

Indicator name	Unit	2025 data
Total duration of employee training	Hours	384,044.06
Average training hours per person	Hours	132.29
Total training hours for female employees	Hours	219,575.24
Average training hours per female employee	Hours	149.17
Total training hours for male employees	Hours	164,468.81
Average training hours per male employee	Hours	114.93
Total training hours for employees at director level and above	Hours	38,706.43
Average training hours per employee at director level and above	Hours	182.58
Total number of training sessions for the year	Sessions	356
Employee training coverage rate	%	100

Promotion and incentives

Anchored in innovation as its core driver, the Company is committed to building a multi-tiered, internationally competitive talent system with strategic focus on three pillars: precisely identifying and cultivating "T-shaped talent" with both professional depth and cross-disciplinary integration capabilities; establishing a sustainable leadership pipeline from emerging talents to industry leaders; and fostering a talent ecosystem of "co-created value and shared growth". Simultaneously, it provides a holistic career development support framework centered on the *Internal Job Competition Management Measures*, instituting a transparent and standardized promotion mechanism that enables fair competition and merit-based advancement, empowering employees to realize personal growth and enhanced professional value.

The Company has established a dual incentive system combining "short-term recognition and long-term alignment", utilizing diverse mechanisms such as spot awards and stock options to deeply align individual talent development with organizational growth. It also cultivates an open and inclusive innovation culture to continuously strengthen employee belonging and cohesion.



Performance management and appeals

To execute group strategy and drive synergistic development between the organization and employees, the Company has implemented an annual performance management system cascading across three levels: group, team, and individual. Aligned with the group's annual objectives, goals are progressively decomposed into business team targets and ultimately individual performance goals. The process encompasses three core phases: goal setting, mid-year review, and year-end evaluation. Through a systematic assessment and feedback mechanism, the system effectively links corporate strategy with employee development—driving team collaboration, ensuring performance delivery, and supporting continuous capability enhancement. Furthermore, each team's goal attainment is tied to corresponding reward and accountability mechanisms, reinforcing organizational execution and ensuring full strategic implementation.

The Company has established a clear performance appeal mechanism to safeguard employees' right to express views and protect their interests during performance management. As stipulated in the *Employee Performance Management System*, if an employee disagrees with their direct supervisor's decision regarding goal setting, performance evaluation, or other related matters and consensus cannot be reached through discussion, they may appeal to their second-line manager or the Human Resources Department. Upon receipt of the appeal, the second-line manager or HR will engage in thorough dialogue with the employee to seek agreement. If no resolution is reached, the final decision will be jointly determined by the head of the employee's business unit (or subsidiary) and HR, ensuring a fair and effective appeal process.

Compensation and benefits

The Company strengthens the foundation of employee rights by refining its policy framework, including the *Employee Handbook*, *Attendance and Leave Management System*, and *Pharmaceutical Expense Subsidy Policy*, to standardize compensation, performance, leave, and benefits—providing multi-dimensional protection encompassing statutory entitlements, livelihood security, and health care.

Compensation and benefits management systems and measures

Compensation management

The *Employee Handbook* specifies that compensation is determined based on position, performance, and potential, supported by an annual salary adjustment mechanism to ensure fairness and motivation.

Performance management

The *Employee Performance Management System* clearly standardizes the end-to-end process of goal setting, performance evaluation, and result application, providing the basis for salary adjustments, bonus disbursement, and related decisions.

Statutory benefits

The *Attendance and Leave Management System* ensures employees' entitlement to statutory leaves, including paid annual leave, parental leave, maternity leave, paternity leave, nursing leave for single-child parents, and sick leave.

Non-statutory benefits

The *Employee Reward Management Measures* establishes diverse recognition programs; the "Pharmaceutical Expense Subsidy Policy" provides medication subsidies for employees and their immediate family members.

Flexible employment protection

The *Intern Management Regulations* standardize intern compensation, insurance, safety, and rights protection.

Employee care

In 2025, the Company planned and implemented diverse cultural activities through hybrid online-offline formats to enhance employee belonging and cultural identity. Leveraging its HR system and digital tools, it automatically sends personalized birthday and work anniversary greetings to employees, reinforcing their sense of being valued through thoughtful touches. Additionally, the labor union actively organized a rich array of cultural, sports, and festive events—including the traditional "Spring Festival Couplets Writing" activity, the "Winning Every Step, Walking in Health" online walking challenge, team-building at Yunye Fengxian Yuli Camp, and Dragon Boat Festival sachet-making workshops. These year-round activities, aligned with major holidays like Spring Festival and Dragon Boat Festival as well as quarterly themes, effectively fostered employee interaction and cultivated a positive, healthy, and collaborative organizational culture.



Traditional folk activity "Writing Spring Festival Couplets"

Hosted couplets writing and "Fu" character gifting to preserve Chinese cultural heritage, create a festive Lunar New Year atmosphere, and strengthen connections with participants.



Spring Festival couplets writing activity

Yunye Fengxian Yuli Camp team building

Organized an outdoor team-building event to enhance collaboration and rapport, alleviate work stress, and strengthen communication and trust among team members.



Yunye Fengxian Yuli Camp activity

"Winning Every Step, Walking in Health" online walking competition

Promoted healthy living through a digital challenge, encouraging company-wide participation, enriching leisure time, and boosting team cohesion.




Poster for the "Winning Every Step, Walking in Health" activity

Dragon Boat Festival sachet making

Held a DIY sachet workshop to experience traditional festival customs, develop hands-on skills, and convey seasonal warmth and good wishes.



Dragon Boat Festival sachet making



Occupational Health

The Company strictly adheres to work safety and occupational disease prevention regulations, maintaining a comprehensive occupational health management system focused on risk control in critical settings such as laboratories. Through standardized management, specialized training, and health monitoring, it holistically safeguards employee occupational health and operational safety.

Governance

The Company strictly complies with national laws including the *Work Safety Law* and the *Law on the Prevention and Control of Occupational Diseases*, ensuring production processes meet regulatory standards. It has established a systematic occupational health and safety management framework underpinned by a long-term control mechanism. A Work Safety Management Committee—comprising a chairperson, executive vice-chair, vice-chairs, and heads of functional departments and the EHS department—serves as the leadership body, with the EHS department acting as the operational arm responsible for developing specialized safety plans and driving implementation of safety management systems to comprehensively protect employee health and operational safety. During the reporting period, the Company recorded no work-related injuries, serious injuries, or occupational disease incidents; there have been no work-related fatalities in the past three years.

In 2025, the Company further improved its occupational health and work safety management system by formulating three core policies: the *All-Employee Work Safety Responsibility System*, the *Safety Inspection and Accident Hazard Rectification System*, and the *Occupational Health Management Regulations*, to enhance the specificity and compliance of these systems. Specifically, the *Safety Inspection and Accident Hazard Rectification System* added inspection items on special equipment management, compliance verification, and implementation of safety training and emergency drills during special inspections, and supplemented relevant reference legal provisions. The *Occupational Health Management Regulations* optimized clause details by standardizing the term "laboratory" to "workplace", clarified the frequency of occupational hazard factor testing and qualification requirements for third-party testing agencies, introduced a requirement for regular submission of occupational hazard declarations to local health supervision authorities, and updated and expanded relevant reference laws and regulations, thereby comprehensively strengthening the institutional foundation for occupational health and work safety management.

Strategy

The Company's occupational health and work safety management centers on the core objective of risk controllability. Based on the characteristics of intensive laboratory operations, it has established a targeted control system. Currently, safety risks primarily manifest as physical hazards in laboratory settings, concentrated in electrical work, chemical management, and equipment operation. Office and production areas present only limited and scattered risks. The overall risk level remains controllable and will not fundamentally alter the Company's business model; the primary impact is confined to employee personal safety, with minimal effects on external partners such as suppliers.

Risk type	Specific description	Impact period	Response measures
Electrical safety	High-load operation of instruments, non-standard temporary wiring, and insulation damage in humid environments may cause electric shock or short-circuit fires.	Short- and medium-term	Conduct insulation tests on laboratory circuits and instruments and maintain a maintenance log for electrical equipment; require operators to wear insulating protective gear; install residual current devices and post safety warning signs in humid areas.
Chemical safety	Involves the storage, handling, and disposal of flammable, corrosive, and toxic reagents, which may lead to leaks, fires, poisoning, or other incidents.	Short- and medium-term	Store reagents according to their properties using specialized storage equipment such as explosion-proof cabinets and corrosion-resistant containers; operators must complete specialized training and pass assessments, and be equipped with full protective gear; standardize classified collection and compliant disposal of chemical waste.
Equipment operation	Improper operation of laboratory equipment, lack of protective facilities, and delayed maintenance may lead to mechanical injuries or equipment explosions.	Short- and medium-term	Operators of special equipment must be certified and undergo quarterly skills refresher training; equipment is fitted with safety interlock devices, and protective facilities are inspected regularly; an inspection and maintenance system is implemented, with complete maintenance records retained.

Opportunity type	Specific description	Impact period	Response measures
Enhancing talent competitiveness	By enhancing the occupational health protection system (e.g., standardized health examinations, optimized protective measures, and strengthened training), the Company enhances employees' sense of belonging and well-being, attracting and retaining high-quality talent to build a competitive advantage in industry talent.	Long-term	Continuously optimize occupational health examination programs to cover risk screening for special positions and wellness check-ups for all employees; conduct regular occupational health training to strengthen risk identification and emergency response capabilities.
Optimizing operational efficiency	Through systematic occupational health management, the Company reduces the risks of work-related injuries and occupational diseases, minimizes production interruptions caused by employee health issues, and enhances overall operational continuity and stability.	Medium-term	Establish a dynamic monitoring mechanism for occupational health in the workplace and regularly conduct occupational hazard factor testing and risk assessments; optimize equipment safety design by installing protective devices and performing periodic calibration to mitigate risks such as mechanical injuries and electric shocks at the source.

Emergency management


The Company has established a robust emergency management system for unexpected incidents and formulated the "Emergency Response Plan for Work Safety Accidents", which includes comprehensive, specialized, and on-site response plans. It defines a three-tier response mechanism and clarifies the responsibilities of the emergency command center and specialized teams such as fire protection, security, and medical rescue. For risks including fires, hazardous chemical leaks, electric shocks, and mechanical injuries, the plan standardizes the entire process—from incident reporting and emergency response to post-incident recovery. The Company maintains emergency supplies such as fire extinguishers and first-aid kits and has established internal and external emergency coordination channels. Additionally, the Company regularly conducts comprehensive drills, on-site response exercises, and full-staff evacuation drills. It also standardizes accident reporting and investigation procedures, requiring timely reporting and thorough investigation of all deviations and abnormal events, followed by targeted corrective and preventive actions to ensure rapid and effective emergency response, prevent recurrence of similar incidents, and comprehensively safeguard both operational continuity and employee safety.

Safety training

Guided by the principle that "everyone participates in safety and everyone safeguards safety", the Company delivers safety training and education through diverse formats such as Safety Month themed activities and sharing sessions on typical safety cases, continuously reinforcing safety red-line awareness and risk prevention capabilities across all employees.

Case **R&D laboratory safety management training**

In December 2025, the Company conducted its annual R&D laboratory safety management training, covering the new *Work Safety Law*, Shanghai's hazardous chemical management regulations, biosafety laboratory operating procedures, and a hazardous chemical leak emergency drill. The training emphasized the "three musts" principle—"safety must be managed alongside business, alongside industry oversight, and alongside production and operations"—and clarified safety responsibilities across departments and roles, aiming to standardize operational procedures, enhance emergency response capabilities, and reinforce laboratory safety defenses.



Impact, risk, and opportunity management


To strengthen risk control, the Company has established a comprehensive safety management system and control measures. Through special inspections and routine patrols, it proactively identifies and mitigates potential hazards. The Company conducts a comprehensive risk identification and assessment annually to dynamically refine its control strategies, ensuring a stable balance between operational continuity and employee safety. Additionally, it regularly performs risk assessments on biosafety, chemicals, equipment, and environmental factors, and implements targeted control measures for high-risk activities such as biological sample handling and chemical use.

Regarding employee health monitoring and examinations, the Company provides regular occupational health check-ups for employees exposed to hazardous factors (such as chemical reagents and radiation) and establishes dedicated health records for them, enabling early identification, tracking, and timely intervention for occupational disease risks, thereby comprehensively safeguarding employees' occupational health.

Supplier safety

Total hours of supplier safety training

75 hours



Indicators and targets

Occupational disease physical examination for employees

Number of employees participating in occupational disease physical examinations

269 persons

Occupational health examination coverage

100%

Compliance rate of occupational hazard factor testing in the workplace

100%

Health and safety training and drills

Total hours of occupational health and work safety training

32 hours

Number of safety drills (fire, toxic gas leaks, etc.)

11 times

Investment in work safety

Total investment in work safety

1.752 million yuan

Work safety training coverage rate

above **95%**

Investment amount for employee work-related injury insurance

2.3568 million yuan

Employee work-related injury insurance coverage rate*

99.24%

Number of work-related fatalities

0 person

Number of workdays lost due to work-related injuries

85.5 days

Occupational disease incidence rate

0%

* Excluding rehired retirees and foreign nationals, the work-related injury insurance coverage rate for all other employees is 100%.

Social Welfare and Inclusive Medical Care

The Company firmly believes that engaging in public welfare activities fulfills its social responsibility and is the key to building a positive corporate image and enhancing employee pride. As an innovative pharmaceutical company, while advancing cutting-edge drug R&D, it places greater emphasis on effectively translating innovations into clinical accessibility and patient affordability, systematically integrating the concept of inclusive healthcare into its business practices—including innovative drug R&D, production assurance, promotion of standardized medication use, and medical capacity building.

Grounded in public welfare concerns and focused on addressing pain points in healthcare, the Company actively responds to national policy directives through concrete actions. Using diverse approaches such as targeted donations, public welfare consultations, and health science communication, it comprehensively supports the upgrading of primary healthcare infrastructure, builds bridges for doctor-patient communication, and enhances public health literacy. The Company steadily advances toward balanced urban-rural medical resource development and public health protection, demonstrating its commitment to corporate social responsibility and setting an exemplary standard for the industry through a series of public welfare initiatives.

In 2025, the Company's core commercial product, toripalimab (TUOYI®), received approval for two new indications in China. This approval brings the total number of approved indications in Chinese mainland to 12, all of which have been included in the National Reimbursement Drug List (NRDL). It is the only anti-PD-1 monoclonal antibody on the list indicated for the treatment of renal cell carcinoma, triple-negative breast cancer, and melanoma, further expanding the range of patients benefiting across tumor types and reducing the medical burden on patients and their families. The Company continues to expand its global commercial network; toripalimab has been approved for marketing in over 40 countries and regions, including China, the United States, the European Union, etc., addressing unmet clinical needs in these markets.

Moreover, as the first domestically developed anti-PD-1 monoclonal antibody recommended by three major authoritative guidelines globally (CSCO/NCCN/ESMO), toripalimab achieved continued breakthroughs in 2025, gaining recognition in 20 authoritative guidelines worldwide, with more than 15 new key recommendations added and several existing recommendations upgraded to the highest level.

Case **Supporting primary healthcare and emergency medical services**

In January 2025, the Company donated 300,000 yuan to the Red Cross Society of Fuping County, Shaanxi Province, to support the development and dissemination of the local medical emergency response system, including the procurement of automated external defibrillators (AEDs) and emergency vehicles for healthcare institutions. This initiative aims to further optimize the layout of primary emergency facilities and substantially enhance regional medical emergency response capabilities. The Company remains steadfast in its commitment to social responsibility, actively aligning with national policy priorities and focusing on improving the quality and capacity of county-level healthcare services. Through tangible actions, it promotes equitable urban-rural medical resource distribution and sets a benchmark for responsible industry leadership.



The Company signing the donation agreement

Case **Pooling high-quality medical resources to build a bridge for doctor-patient communication**

To help more lung cancer patients and their families access high-quality medical care, in February 2025, the Company co-hosted the "Chasing the Light, Caring for Lungs" public welfare consultation event with partner organizations. Centered on five thematic live streams, the event connected 23 cities nationwide and brought together 44 lung cancer specialists, offering one-stop, professional diagnosis and treatment consultations through online free clinics and relay Q&A sessions. The event provided detailed case-specific answers to nearly 100 lung cancer patients, attracted 200,000 viewers, received over 130,000 likes, and engaged nearly 1,000 patients and family members in interactive Q&A, effectively establishing a convenient channel for doctor-patient communication.



The Company conducting an online public welfare consultation

Case **The Company launches the "Medical Care Road" public welfare science popularization activity for cancer patients**

In April 2025, the Company-supported "Medical Care Road" public welfare science communication campaign for cancer patients officially launched. Focused on core public concerns—including cancer prevention, disease education, emotional support, and psychological interventions—the campaign organized multiple online and offline public science livestreams nationwide. It brought together dozens of renowned experts and numerous frontline clinicians, reaching over 55,000 audience members, collecting and answering more than 2,000 questions. This series not only effectively disseminated fundamental knowledge about cancer but also significantly enhanced public understanding of the disease and capacity for recovery management, generating broad social impact.

Case **"Exploring 100 Questions in Urology" public health science popularization campaign**

The Company provides public welfare support for the "Exploring 100 Questions in Urology" public health science communication campaign. Focusing on urological cancers and related conditions, the campaign continuously disseminates evidence-based diagnosis and treatment concepts to the public through participation by authoritative medical experts and systematic content delivery. Leveraging online channels to reach a broad audience, the initiative effectively enhances public awareness of early screening, standardized treatment, and rational medication use, thereby creating favorable conditions for the appropriate real-world application of innovative medicines.



"Exploring 100 Questions in Urology" event

Key performance

Indicator name	Unit	2025	2024
Investment in social welfare	Ten thousand yuan	2,995.79	2,330.94
Number of individuals assisted by the Company	Persons	5,263	4,769

Industry Empowerment

The Company consistently adheres to a development philosophy of openness, collaboration, co-construction, and shared success. It proactively fulfills its industry and social responsibilities, leveraging its core expertise and influence to actively participate in multiple industry organizations and deeply engage in ecosystem co-building. The Company focuses on cutting-edge industry research, contributing its experience as a market leader to industry studies and report development, while also committing substantial resources to industry-education integration and talent cultivation to support the industry's talent pipeline. Through dual efforts in empowering industry research and implementing industry-academia collaboration, the Company continuously fosters resource sharing and outcome exchange, laying a solid practical and human capital foundation for the industry's high-quality and sustainable development. In 2025, the Company's subsidiary Shanghai Junshi Biotechnology Co., Ltd. participated in drafting the group standard *Technical Requirements for Digital Traceability Throughout the Drug Production Process: Production Data Collection and Monitoring*, applying its professional capabilities to advance industry standardization and normalization.

Company name	Position in industry organizations
Junshi Biosciences	Executive council member of the All-China Federation of Industry & Commerce Medical & Pharmaceutical Industry Chamber
	Council member of the Recombinant Drug Branch of the China Biochemical Pharmaceutical Industry Association
	Council member of the China Pharmaceutical Innovation and Research Development Association
	Vice-chair of the Yangtze River Delta Pharmaceutical Innovation and Development Alliance
	Vice-president of the Shanghai Federation of Industry and Commerce, Chamber of Commerce for the Biomedical Industry
	Member of the Shanghai Industrial Technology Innovation Promotion Association
	Chair of the Shanghai Biopharmaceutical Industry Innovation Alliance
	Council member of the Shanghai Pudong New Area Bio-Industry Association
	Council member of the Shanghai Biopharmaceutical Industry Association
	Member of the Shanghai Intelligent Manufacturing Industry Association
	Council member of *Shanghai Informatization*
	Corporate member of the council of the Journal Academic Center of Jiangsu Province Hospital
	Executive council member of the All-China Federation of Industry & Commerce Medical & Pharmaceutical Industry Chamber (Zou Jianjun); Sichuan Medical Security Research Association
	Chongqing Medical Security Research Association
	Shaanxi Provincial Medical Insurance Research Association
	Guizhou Medical Security Research Association

Company name	Position in industry organizations
Junshi Biosciences	Xinjiang Medical Security Research Association
	Shaanxi Pharmaceutical Price Association
	Beijing Medical Insurance Association
	Tianjin Medical Insurance Association
	Liaoning Provincial Medical Insurance Research Association
	Hubei Medical Security Research Association
	Guangdong Medical Insurance Research Association
	Guangxi Medical Insurance Research Association
	Hainan Provincial Social Security Research Association
	Shandong Medical Security Research Association
	Shanghai Medical Insurance Association
Suzhou Union Biopharm Co., Ltd.	Council member of the Suzhou Pharmaceutical Association
	Member of the Wujiang Economic and Technological Development Zone Chamber of Commerce
Shanghai Junshi Biotechnology Co., Ltd.	Member of the Shanghai Lingang Industrial Park Enterprise Association

Case

The Company's deep involvement in the AI+ healthcare industry research

In December 2025, the industry research report *2025 AI+ Healthcare Industry Application Atlas* was officially released. Jointly compiled and published by China Business Network, the Shanghai Service Federation, and the Shanghai Artificial Intelligence Research Institute, the report provides a panoramic reference for the industry's high-quality development. The Company played a significant role in this research, contributing its practical experience and landmark case studies as an industry leader in AI-driven drug discovery.

Case

Expanding the university-enterprise cooperation landscape and promoting collaborative talent cultivation

In 2025, the Company deepened its engagement in industry-education integration, actively expanding its university-enterprise collaboration ecosystem and fulfilling its talent development and social responsibilities. It established strategic partnerships with universities including China Pharmaceutical University, Zhejiang University, and Shenyang Pharmaceutical University, focusing on joint cultivation of professional master's students, enterprise practice visits, and continuing education for working professionals, thereby building a diversified, end-to-end collaborative talent development system. During the reporting period, the Company jointly trained 15 professional master's students from China Pharmaceutical University and invested 470,000 yuan in dedicated talent development funding to support students in balancing academic research and career advancement.



Key Performance

Economic Performance

Indicator name	Unit	2025 data
Operating revenue	Ten thousand yuan	249,842.03
Total assets	Ten thousand yuan	1,238,232.69
Total number of major public opinion incidents	Cases	0

Governance Performance

Indicator name	Unit	2025 data	2024 data
Corporate governance			
Number of General Meetings	Times	2	4
Number of proposals reviewed and approved by the General Meeting	Items	23	22
Total number of board members	Persons	14	14
Including: Number of female directors	Persons	3	4
Including: Percentage of female directors	%	21.43	28.57
Including: Number of executive directors	Persons	8	8
Including: Percentage of executive directors	%	57.14	57.14
Including: Number of independent non-executive directors	Persons	5	5
Including: Percentage of independent non-executive directors	%	35.71	35.71
Number of full Board Meetings	Times	10	13
Number of Board Audit Committee meetings	Times	4	5
Number of Board Nomination Committee meetings	Times	1	5
Number of Board Strategic Committee meetings	Times	1	1
Number of Board Remuneration and Appraisal Committee Meetings	Times	4	6
Number of Board Compliance Committee meetings	Times	1	/
Average board attendance rate	%	100	100
Number of board training sessions conducted	Sessions	4	/
Number of ESG training sessions conducted	Times	4	/
Total number of participants in ESG training	Person-times	56	/
Number of internal control and compliance training sessions	Sessions	1	/
Number of participants in internal control and compliance training	Person-times	913	/
Anti-bribery and anti-corruption			
Total number of corruption incidents	Cases	0	/
Number of contracts with business partners terminated or not renewed due to corruption-related violations	Cases	0	/
Number of anti-bribery and anti-corruption training sessions conducted	Times	61	29
Total number of directors covered by anti-bribery and anti-corruption training	Persons	14	14

Indicator name	Unit	2025 data	2024 data
Percentage of directors covered by anti-bribery and anti-corruption training	%	100	100
Total number of management personnel covered by anti-bribery and anti-corruption training	Persons	7	7
Percentage of management personnel covered by anti-bribery and anti-corruption training	%	100	100
Total number of employees covered by anti-bribery and anti-corruption training	Persons	2,903	2,578
Percentage of employees covered by anti-bribery and anti-corruption training	%	100	100
Anti-unfair competition			
Number of anti-unfair competition training sessions	Sessions	4	/
Total duration of anti-unfair competition training	Hours	4	/
Average duration of anti-unfair competition training per person	Hours	1	/
Number of participants in anti-unfair competition training	Person-times	2,605	/
Number of people covered by anti-unfair competition training	Persons	2,488	/
Total number of litigation or administrative penalty cases for violations of fair competition laws	Cases	0	0
Total fines imposed for violations of fair competition laws	Yuan	0	0
Information disclosure			
Number of ad-hoc announcements disclosed	Items	77	81
Number of periodic reports disclosed	Items	4	4

Environmental Performance

Indicator name	Unit	2025 data	2024 data
Climate change response[1]			
Total greenhouse gas emissions	Tonnes of carbon dioxide equivalent	35,350.76	26,800.75
Including: Scope 1 greenhouse gas emissions	Tonnes of carbon dioxide equivalent	3,039.21	5,307.75
Including: Scope 2 greenhouse gas emissions	Tonnes of carbon dioxide equivalent	32,311.55	21,493
Environmental management			
Total annual environmental protection investment	Ten thousand yuan	499.03	423.55
Annual investment in environmental protection and energy-saving technology upgrades	Ten thousand yuan	120	/
Number of emergency drills conducted for sudden environmental risk incidents	Sessions	3	/
Number of participants in emergency drills for sudden environmental risk incidents	Person-times	165	/
Number of environmental management training sessions conducted	Times	11	11
Total hours of environmental management training	Hours	15.5	/
Number of participants in environmental management training	Person-times	727	/
Number of participants in environmental awareness and public welfare activities	Person-times	22	/
Number of violations of environmental laws and regulations	Cases	0	0
Amount of significant administrative penalties imposed by ecological and environmental authorities for environmental incidents during the reporting period	Yuan	0	0
Energy utilization[2]			
Combined energy consumption	Tonnes of standard coal	10,377.38	9,702.17
Energy use intensity	Tonnes of standard coal per million yuan in revenue	4.15	4.98

Indicator name	Unit	2025 data	2024 data
Direct energy consumption	Tonnes of standard coal	1,841.18	4,999.5
Including: Gasoline	Tonnes	74.24	107.25
Including: Diesel	Liters	10,159.65	951.93
Including: Natural gas	Cubic meters	1,292,529	3,639,460
Indirect energy consumption	Tonnes of standard coal	8,536.2	4,702.67
Including: Electricity	MWh	35,656.63	38,264.2
Including: Steam	Million kilojoules	121,746.79	/
Clean energy consumption	kWh	11,412	/
Water resource utilization			
Water withdrawal	Tonnes	508,211	/
Water discharge	Tonnes	316,991	/
Total water consumption	Tonnes	191,220	416,929
Water consumption intensity per million yuan in revenue	Tonnes per million yuan in revenue	76.54	213.99
Pollutant emission[3]			
Waste gas			
Nitrogen oxides (NO_x) emissions	Tonnes	0.079	0.3
Sulfur oxides (SO_x) emissions	Tonnes	0.003	0.033
Particulate matter (PM) emissions	Tonnes	/	0.009
Volatile organic compounds (VOCs) emissions	Tonnes	0.061	0.09
Approved volatile organic compounds (VOCs) emissions	Tonnes	0.87	/

Indicator name	Unit	2025 data	2024 data
Wastewater			
Total amount of wastewater discharge	Tonnes	120,107	122,714
Chemical oxygen demand (COD) emissions	Tonnes	7.84	4.53
Approved chemical oxygen demand (COD) emissions	Tonnes	66	/
Ammonia nitrogen (NH_3-N) emissions	Tonnes	0.41	0.31
Approved ammonia nitrogen (NH_3-N) emissions	Tonnes	2.5	/
Waste management			
Total domestic waste	Tonnes	230	/
Domestic waste intensity	Tonnes per million yuan in revenue	0.09	/
Total non-hazardous (general) solid waste	Tonnes	187.1	163.74
Non-hazardous (general) solid waste intensity	Tonnes per million yuan in revenue	0.075	0.084
Total hazardous solid waste	Tonnes	232.06	169.31
Hazardous solid waste intensity	Tonnes per million yuan in revenue	0.093	0.087
Packaging materials			
Packaging materials used for finished products	Tonnes	22.88	28.94

[1] Greenhouse gas emissions data are calculated in accordance with the *Greenhouse Gas Protocol*.

[2] Energy consumption data are calculated based on the *General Rules for Calculation of the Comprehensive Energy Consumption* (GB/T 2589–2020); the grid electricity emission factor is sourced from the *Announcement on the 2023 CO_2 Emission Factor for Electricity Generation*.

[3] Shanghai Junshi Biotechnology Co., Ltd., a subsidiary of Junshi Biosciences Co., Ltd., has disclosed environmental information in accordance with applicable laws. No exceedances of emission limits occurred in 2025. The approved emissions listed in the table above pertain solely to data from Shanghai Junshi Biotechnology Co., Ltd..

Social Performance

Indicator name	Unit	2025 data	2024 data
Product quality			
Number of product recalls	Cases	0	0
Product recall rate	%	0	0
Number of product quality improvement training sessions held	Sessions	17	/
Total duration of product quality improvement training	Hours	14,000	/
Number of people covered by product quality improvement training	Persons	803	/
Pharmacovigilance marketing training coverage rate	%	100	100
Total number of personnel trained in pharmacovigilance[1]	Persons	3,011	2,743
Total number of incidents involving non-compliance with regulations on product and service information and labeling	Cases	0	0
Total number of incidents involving non-compliance with regulations on marketing communications (including advertising, promotion, and sponsorship)	Cases	0	0
R&D and innovation			
R&D expenditure	Ten thousand yuan	134,212.32	127,527.01
Ratio of total R&D expenditure to operating revenue	%	53.72	65.45
Total number of R&D personnel	Persons	640	620
Total number of R&D personnel holding master's degrees or higher	Persons	299	284
Total number of R&D personnel holding bachelor's degrees	Persons	317	312
Total number of R&D personnel holding associate degrees	Persons	24	24
Proportion of R&D personnel holding master's degrees or higher	%	46.72	45.81
Proportion of R&D personnel holding bachelor's degrees	%	49.53	50.32
Proportion of R&D personnel holding associate degrees	%	3.75	3.87
Number of patents held	Cases	193	175
Number of invention patents held	Cases	88	70
Number of newly granted patents during the year	Cases	19	32
Number of patents under examination	Cases	291	284
Number of copyrights held	Cases	10	10
Number of trademarks held	Cases	177	/
Incidents involving violations of technology ethics	Cases	0	0
Employees			
Total number of employees	Persons	2,903	2,578
Number of newly hired employees	Persons	945	629
Number of newly hired full-time employees	Persons	944	629
By gender			
Number of female employees	Persons	1,472	1,350
Number of male employees	Persons	1,431	1,228
By type of employment			
Number of employees under labor contracts	Persons	2,884	2,566
Others (re-employed retirees and part-time contract workers)	Persons	19	12
By age			
Number of employees aged 30 and below	Persons	882	777
Number of employees aged 31 to 40[2]	Persons	1,519	1,718
Number of employees aged 41 to 50	Persons	418	
Number of employees aged 51 and above[3]	Persons	84	83
By rank			
Number of director level and above employees	Persons	212	201
Number of female employees in director level and above	Persons	99	99
Number of manager level employees	Persons	557	560
Number of female employees in manager level	Persons	281	290
Number of grassroots employees	Persons	2,134	1,817
By region			
Employees working in Chinese mainland	Persons	2,869	2,548
Employees working in Hong Kong, Macao, and Taiwan	Persons	3	1
Employees working in other countries	Persons	31	29

Indicator name	Unit	2025 data	2024 data
Total employee turnover rate	%	17.5	19.66
By gender			
Including: Male employee turnover rate	%	17.9	21.58
Including: Female employee turnover rate	%	17.12	17.83
By age			
Including: Turnover rate of employees aged 30 and below	%	20.4	22.3
Including: Turnover rate of employees aged 31 to 40[2]	%	16.95	18.85
Including: Turnover rate of employees aged 41 to 50	%	13.46	
Including: Turnover rate of employees aged 51 and above[3]	%	15.15	9.78
By region			
Including: Turnover rate of employees working in Chinese mainland	%	17.56	19.75
Including: Turnover rate of employees working in Hong Kong, Macao and Taiwan	%	0	0
Including: Turnover rate of employees working in other countries	%	13.89	12.12
Number of ethnic minority employees	Persons	112	71
Employee social insurance coverage rate[4]	%	99.24	99.2
Confirmed incidents of discrimination, forced labor, and child labor	Cases	0	0
Occupational health and safety			
Number of employees participating in occupational disease physical examinations	Persons	269	184
Occupational health examination coverage rate	%	100	100
Total hours of occupational health and work safety training	Hours	32	18
Compliance rate of occupational hazard factor testing in the workplace	%	100	/
Number of safety drills (fire, toxic gas leaks, etc.)	Times	11	9
Total investment in work safety	Ten thousand yuan	175.2	83.08
Investment amount for employee work-related injury insurance	Ten thousand yuan	235.68	178.05
Employee work-related injury insurance coverage rate[4]	%	99.24	99.2
Number of work-related injuries (minor and above)	Persons	5	2
Number of work-related fatalities	Persons	0	0
Number of workdays lost due to work-related injuries	Days	85.5	49
Occupational disease incidence rate	%	0	0

Indicator name	Unit	2025 data	2024 data
Talent development and training			
Total duration of employee training	Hours	384,044.06	156,194.56
Average training hours per person	Hours	132.29	60.59
Including: Total training hours for female employees	Hours	219,575.24	71,567.61
Including: Average training hours per female employee	Hours	149.17	53.01
Including: Total training hours for male employees	Hours	164,468.81	84,626.95
Including: Average training hours per male employee	Hours	114.93	68.91
Including: Total training hours for director-level and above employees	Hours	38,706.43	4,549.68
Including: Average training hours per director-level and above employee	Hours	182.58	22.64
Total number of training sessions for the year	Sessions	356	484
Employee training coverage rate[5]	%	100	100
Percentage of employees receiving regular performance and career development reviews	%	100	100
Suppliers			
Number of suppliers		2,011	2,298
Including: Number of domestic suppliers		1,849	2,168
Total hours of supplier safety training	Hours	75	28
Data security and customer privacy protection			
Number of confirmed data security incidents	Cases	0	0
Number of confirmed customer privacy breach incidents	Cases	0	0
Charitable donations			
Amount of social welfare investment	Ten thousand yuan	2,995.79	2,330.94
Value of medicine donations	Ten thousand yuan	1,007.52	1,107.16
Number of individuals assisted by the Company	Persons	5,263	4,769

[1] This figure is based on data from the Company's Training Management System (TMS) and includes former employees.

[2] The 2024 statistical scope covers employees aged 31 to 49.

[3] The 2024 statistical scope covers employees aged 50 and above.

[4] Excluding rehired retirees and foreign nationals, the coverage rate for other employees is 100%.

[5] Training coverage is 100% for male employees, female employees, and employees at all job levels.

SSE Index Table

Disclosure requirements		Corresponding sections of this report	Page number	Statement of undisclosed issues
Environment	Climate change response	Climate change response	55-57	
	Pollutant emissions	Pollutant and waste management	51, 52, 53	
	Waste management	Pollutant and waste management	53-54	
	Ecosystem and biodiversity conservation	/	/	The Company's main business does not involve ecologically sensitive areas and has no significant impact on ecosystems. According to the importance assessment results, the Company does not disclose information related to ecosystem and biodiversity protection.
	Environmental compliance management	Environmental compliance management	45-46	
	Energy utilization	Resource and energy use	47-48	
	Water resource utilization	Resource and energy use	49-50	
	Circular economy	Circular economy	58	
Social	Rural revitalization	/	/	The Company's main business is the research and development of innovative biopharmaceuticals. Based on the actual business situation and importance assessment results, the Company has not disclosed information related to rural revitalization.
	Social contribution	Social welfare and inclusive healthcare	71-72	
	Innovation-driven development	Innovation-driven development Intellectual property protection	33-43	
	Technology ethics	Innovation-driven development	34	
	Supply chain security	Supply chain management	29-32	
	Equal treatment of small and medium-sized enterprises	Supply chain management	32	

Disclosure requirements		Corresponding sections of this report	Page number	Statement of undisclosed issues
Social	Product and service safety and quality	Product quality and service	22-26	
	Data security and customer privacy protection	Data security and customer privacy	27-28	
	Employees	Employee rights Occupational health Talent development	60-70	This report divides employee topics into three self-disclosure topics: employee rights, occupational health and safety, and talent training and development, and discloses them separately.
Governance	Due diligence	ESG management framework	10	
	Stakeholder engagement	Stakeholder engagement	9	
	Anti-bribery and anti-corruption	Business ethics	19-20	
	Anti-unfair competition	Business ethics	20	
Topics for self-disclosure	Intellectual property protection	Intellectual property protection	42-43	
	Industry exchange and cooperation	Industry empowerment	73-74	
	Inclusive healthcare	Social welfare and inclusive healthcare	71-72	
	Employee rights	Employee rights	60-62	
	Occupational health and safety	Occupational Health	67-70	
	Talent training and development	Talent development	63-66	
	Compliant operation	Compliant operation	17-18	
	Corporate governance	Corporate governance	12-14	

HKEX Index Table

Hierarchy	Content	Chapter name	Page number
Environment			
A1: Emissions			
General disclosures	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a material impact on the issuer, regarding emissions, discharges to water and land, and the generation of hazardous and non-hazardous waste.	Pollutant and waste management	51
Key performance indicator A1.1	Types of emissions and associated emission data.	Key performance table	75-79
Key performance indicator A1.3	Total amount of hazardous waste generated (in tonnes) and, where applicable, its density (e.g., per unit of production, per facility).	Pollutant and waste management	54
Key performance indicator A1.4	Total amount of non-hazardous waste generated (in tonnes) and, where applicable, its density (e.g., per unit of production, per facility).	Pollutant and waste management	54
Key performance indicator A1.5	Description of the emission targets set and the steps taken to achieve them.	Pollutant and waste management	54
Key performance indicator A1.6	Description of the methods used to treat hazardous and non-hazardous waste, as well as of the waste reduction targets set and the steps taken to achieve them.	Pollutant and waste management	53-54
A2: Resource use			
General disclosures	Policies for the efficient use of resources, including energy, water, and other raw materials.	Water resource management	49-50
Key performance indicator A2.1	Total direct and/or indirect energy (e.g., electricity, gas, or oil) consumption (in thousands of kilowatt-hours) and density (e.g., per unit of production, per facility), by type.	Resource and energy use	48
Key performance indicator A2.2	Total water consumption and density (e.g., per unit of production, per facility).	Water resource management	69
Key performance indicator A2.3	Description of the energy efficiency goals set and the steps taken to achieve them.	Resource and energy use	47-48
Key performance indicator A2.4	Description of any issues in accessing suitable water sources, as well as of the water efficiency targets set and the steps taken to achieve them.	Water resource management	49-50
Key performance indicator A2.5	Total amount (in tonnes) of packaging material used in finished products and, where applicable, the amount per unit of production.	Circular economy	58
A3: Environment and natural resources			
General disclosures	Policies to reduce the issuer's significant impact on the environment and natural resources.	Environmental compliance management	45-46

Hierarchy	Content	Chapter name	Page number
Key performance indicator A3.1	Description of the significant impacts of business activities on the environment and natural resources and of the actions taken to manage these impacts.	Environmental compliance management	45-47
Social			
B1: Employment			
General disclosures	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a material impact on the issuer, regarding remuneration and termination, recruitment and promotion, working hours, holidays, equal opportunity, diversity, anti-discrimination, and other terms and conditions of employment.	Employee rights	60-62
Key performance indicator B1.1	Total number of employees by gender, employment type (e.g., full-time or part-time), age group, and geographical region.	Key performance table	75-79
Key performance indicator B1.2	Employee turnover rate by gender, age group, and region.	Key performance table	75-79
B2: Health and safety			
General disclosures	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a material impact on the issuer, regarding the provision of a safe working environment and protection of employees from occupational hazards.	Occupational Health	67
Key performance indicator B2.1	Number and rate of work-related fatalities in each of the past three years (including the reporting year).	Occupational Health	68
Key performance indicator B2.2	Days lost due to work-related injuries.	Occupational Health	70
Key performance indicator B2.3	Description of the occupational health and safety measures adopted, as well as of the related implementation and monitoring methods.	Occupational Health	67-70
B3: Development and training			
General disclosures	Policies relating to enhancing employees' knowledge and skills in performing their job duties. Describe training activities.	Talent development	63
Key performance indicator B3.1	Percentage of employees who received training, by gender and employee category (e.g., senior management, middle management).	Talent development	64
Key performance indicator B3.2	Average number of training hours completed per employee, by gender and employee category.	Talent development	65
B4: Labour code			
General disclosures	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a material impact on the issuer, regarding the prevention of child labor and forced labor.	Employee rights	61
Key performance indicator B4.1	Description of measures taken to review recruitment practices to prevent child and forced labor.	Employee rights	61
Key performance indicator B4.2	Description of steps taken to address violations once identified.	Employee rights	61

Hierarchy	Content	Chapter name	Page number
B5: Supply chain management			
General disclosures	Policies for managing environmental and social risks in the supply chain.	Supply chain management	29
Key performance indicator B5.1	Number of suppliers by region.	Key performance table	75-79
Key performance indicator B5.2	Description of supplier engagement practices, the number of suppliers to whom such practices are applied, and the related implementation and monitoring methods.	Supply chain management	30
Key performance indicator B5.3	Description of practices for identifying environmental and social risks at each stage of the supply chain, along with the associated implementation and monitoring methods.	Supply chain management	31-32
Key performance indicator B5.4	Description of practices promoting the use of environmentally friendly products and services in supplier selection, along with the related implementation and monitoring methods.	Supply chain management	31-32
B6: Product liability			
General disclosures	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a material impact on the issuer, regarding the health and safety, advertising, labeling, and privacy of products and services offered, as well as related remedies.	Product quality and service	22-23
Key performance indicator B6.1	Percentage of total products sold or shipped that were recalled for safety and health reasons.	Product quality and service	24
Key performance indicator B6.2	Number of complaints received regarding products and services and the manner in which they were addressed.	Product quality and service	24
Key performance indicator B6.3	Description of practices relating to the maintenance and protection of intellectual property rights.	Intellectual property protection	42-43
Key performance indicator B6.4	Description of the quality verification process and product recall procedures.	Product quality and service	24
Key performance indicator B6.5	Description of the consumer data protection and privacy policy, along with its implementation and monitoring methods.	Data security and customer privacy	27-28
B7: Anti-corruption			
General disclosures	Information on: (a) policies; and (b) compliance with relevant laws and regulations that have a material impact on the issuer, regarding the prevention of bribery, extortion, fraud, and money laundering.	Business ethics	19
Key performance indicator B7.1	Number and outcome of corruption cases brought against the issuer or its employees that were resolved during the reporting period.	Business ethics	20
Key performance indicator B7.2	Description of anti-corruption preventive measures and whistleblowing procedures, along with their implementation and monitoring methods.	Business ethics	20
Key performance indicator B7.3	Description of anti-corruption training provided to directors and employees.	Business ethics	20
B8: Community investment			
General disclosures	Policies on community engagement to understand the needs of the communities in which it operates and to ensure that its business activities take into account the interests of the community.	Social welfare and inclusive healthcare	71
Key performance indicator B8.1	Focus areas of community contributions (e.g., education, environmental issues, labor needs, health, culture, sports).	Social welfare and inclusive healthcare	71-71

Hierarchy	Content	Chapter name	Page number
Key performance indicator B8.2	Resources (e.g., financial or time-based) allocated to focus areas.	Social welfare and inclusive healthcare	72
Climate-related disclosures			
Governance	The governance body responsible for overseeing climate-related risks and opportunities.	Climate change response	55
	Management's role in the governance processes, controls, and procedures used to monitor, manage, and oversee climate-related risks and opportunities.		
Strategy	Climate-related risks and opportunities that may affect its cash flows, access to financing, or cost of capital in the short, medium, or long term.		56
	The current and expected impact of climate-related risks and opportunities on their business models and value chains.		
	The impact of climate-related risks and opportunities on their strategies and decision-making.		
Risk management	Processes and policies for identifying, assessing, prioritizing, and monitoring climate-related risks.		57
	Processes for identifying, assessing, prioritizing, and maintaining monitoring climate-related opportunities (including information on whether and how issuers use climate-related scenario analysis to identify climate-related opportunities).		
	How, and to what extent, the processes for identifying, assessing, prioritizing, and monitoring climate-related risks and opportunities are integrated into the issuer's overall risk management process.		
Indicators and objectives	Total absolute greenhouse gas emissions (in metric tonnes of CO_2 equivalent) for the reporting period, disaggregated into: (a) Scope 1 GHG emissions; (b) Scope 2 GHG emissions; and (c) Scope 3 GHG emissions.		
	Methods used to quantify greenhouse gas emissions.	Key performance table	75-79
	Climate-related qualitative and quantitative targets established to monitor progress toward strategic objectives.	Climate change response	57

Reader Feedback Form

Thank you for reading this report! Please share your valuable comments or suggestions with us to help improve future reports and better meet your information needs.

1. Which of the following best describes you?

☐ Government agency ☐ Media/public ☐ Employee ☐ Shareholder ☐ Partner
☐ Customer ☐ Social organization ☐ Regulatory authority
☐ Other (please specify)

2. What would you like to know from this report?

☐ Company profile ☐ Financial performance ☐ Stakeholder engagement
☐ Workplace safety ☐ Partner-related information ☐ Employment and working conditions
☐ Energy conservation and emissions reduction ☐ Philanthropy ☐ Climate change response
☐ Other (please specify)

3. Do you find the content and layout of the report helpful in finding relevant information?

☐ Yes ☐ No

4. What is the most satisfying aspect of this report?

☐ About Junshi Biosciences ☐ ESG governance ☐ Stakeholder engagement ☐ Corporate governance ☐ Business ethics
☐ Products and services ☐ Information security ☐ Supply chain management ☐ R&D and innovation ☐ Environmental compliance
☐ Resource and energy use ☐ Pollutants and waste ☐ Climate change response ☐ Employees ☐ Community engagement
☐ Accessible healthcare ☐ Industry empowerment

5. What needs to be further developed in this report?

☐ About Junshi Biosciences ☐ ESG governance ☐ Stakeholder engagement ☐ Corporate governance ☐ Business ethics
☐ Products and services ☐ Information security ☐ Supply chain management ☐ R&D and innovation ☐ Environmental compliance
☐ Resource and energy use ☐ Pollutants and waste ☐ Climate change response ☐ Employees ☐ Community engagement
☐ Accessible healthcare ☐ Industry empowerment

6. Any other comments or suggestions on this report.

Your information: _____ Name: _____ Company: _____

Position: _____ Contact number: _____ Email: _____